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Abstract 
 Antibiotics are one of the greatest accomplishments in the field of science. They have 
been extensively used since the time of their discovery. Amongst all the antibiotics, the -
lactam class of antibiotics have been the most clinically used agents. However, the process of 
bacterial resistance towards the antibiotics is becoming an alarming situation in the present 
time. Due to the wide spread use of antibiotics, many Gram-positive and Gram-negative 
pathogens developed resistance against them. Various pathways are known via which the 
bacteria develop resistance towards the -lactam antibiotics, among which, the production of 
-lactamase enzymes is the major cause of bacterial resistance. Presently, many 
pharmaceutical companies and research groups are still interested in developing novel 
cephalosporin derivatives, which would act as antibiotic as well as -lactamase inhibitor. The 
Dmitrienko research group at the University of Waterloo has been developing novel C3ʹ 
benzoylthio cephalosporin derivatives. These potential agents are proposed to possess extended 
spectrum activity against pathogens that have developed multidrug resistance (also called 
“Superbugs”). Preclinical pharmacokinetic studies of these novel C3ʹ benzoylthio 
cephalosporin derivatives will be conducted after their synthesis. The availability of core 
isotopic labelled cephalosporin will permit efficient synthesis of internal standards for any 
novel cephalosporin derivative. The main goal of this thesis work was to synthesize a multiply 
deuterated cephalosporin core. When this project was initiated, a survey of the literature 
revealed a previous attempt to perform H/D exchange at C2 position of cephalosporin 
sulfoxides but no attempts to incorporate deuterium at C3ʹ has been reported. In this study, C2 
and C3ʹ of cephalosporin core were the proposed sites to incorporate deuterium. The first 
objective was to perform a H/D exchange at the C2 position of a cephalosporin core. A H/D 
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exchange reaction was performed with cephalosporin sulfoxide 3.3 using a mixture of benzene 
and D2O at 80 oC to give 78% deuterium exchange at the C2 of 3.3 as determined by 1H NMR. 
In order to increase the deuterium exchange another experimental condition were used in 
which, compound 3.16 (benzhydryl ester of 7-ACA, phenylacetylated at C7) was heated at 50 
oC in presence of DMSO and Methanol-OD. NMR studies revealed that 90.2% deuterium 
incorporation had been achieved at each of the prochiral positions C2 of 3.16. After the 
successful completion of objective 1, the second objective was to synthesize a C3ʹ 
monodeuterated derivative. Eventually after certain attempts, C3ʹ hydroxyl cephalosporin 3.20 
was oxidized to give the corresponding aldehyde 3.21, which was reduced by sodium 
borodeuteride to give the monodeuterated C3ʹ hydroxyl derivative 3.27. The third objective of 
this thesis work was to combine the results of H/D exchange at C2 and deuterium incorporation 
at C3ʹ using functional group interconversion to synthesize a trideuterated cephalosporin 
analogue. The core trideuterated C3ʹ alcohol 3.44 was synthesized from 3.11 (7-ACA) in 10 
steps with an overall yield of 5.9%. In order to reduce the number of steps and to increase the 
overall yield a modified route was achieved to synthesize trideuterated cephalosporin 3.44 in 8 
steps starting from 3.11 (7-ACA) with an overall yield of 19% and a isotopic purity of 87.5% 
(determined by NMR spectroscopy). Mass spectrometric analysis of 3.44 indicates that the 
ratio of trideuterated to dideuterated molecules in material is 5 to 1. 
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Chapter 1 
Introduction 
1.1 Antibiotics  
 The discovery of antibiotics is believed to be one of the most important 
accomplishments in the history of drug development.1 Antibiotics have been derived from 
natural products or synthesized chemically. There has been enormous development in the field 
of novel antibiotic discovery in the last seven decades.2 Based on their chemical structures, 
antibiotics have been classified as -lactam antibiotics, aminoglycosides, tetracyclines, 
macrolides, streptogramins, quinolones, glycopeptides, polyketides and oxazolidinones (Figure 
1.1).3 The β-lactams are the most extensively used and developed classes of antibiotics, and 
account for more than 50% of antibiotic prescriptions yearly.3 Figure 1.2 illustrates the timeline 
for discovery of antibiotics from the 1930s to the 2000s.2 
 
Figure 1.1: Examples from several classes of antibiotics used clinically.  
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 Since their discovery, antibiotics they have been used extensively to cure bacterial 
infections.4 It is believed that the overuse of antibiotics is the prime cause of bacterial 
resistance.5 However, it has also been documented that bacterial resistance to antibiotics has 
existed from before the time of their discovery and is an ancient phenomenon.6 Gram-negative 
pathogens are the most effective at developing resistance through various mechanisms which 
are listed in section 1.3.7  
 
Figure 1.2: The major clinically used antibiotics and type of resistant species are shown in the 
timeline for decade of antibiotic evolution. Green represents synthetic derivatives; black are 
natural product origin derivatives; major antibiotic classes are shown in bold; red represents the 
technology used for their discovery; Gram-positive bacteria are shown in purple and Gram-
negative bacteria in pink.2 
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1.2  -Lactam Antibiotics 
 -Lactam antibiotics have been the most used antibiotics since the time of their 
introduction into clinical practice.8 All -lactam antibiotics contain a four membered ring 
cyclic amide (lactam) ring. Depending on their structural difference in the non-lactam part, -
lactam antibiotics have been classified into five major classes namely: penicillins, 
cephalosporins, carbapenems, penems and monobactams. Figure 1.3 represents the 
representative structures of each class in which the rings shown in red color represent the 
lactam ring.1,9  
 
Figure 1.3: Representative structures from each class of β-lactam antibiotics.1 
 The penicillins were the first β-lactam antibiotics to be discovered in 1928. Alexander 
Fleming observed that a strain of Penicillium mould produced an agent which had antibacterial 
activity and which was later named penicillin.10–12 Numerous attempts to discover novel 
penicillin derivatives were carried out by several research groups around the globe in the late 
1940s.13 Florey and Chain from the University of Oxford demonstrated the safe and effective 
use of penicillins via subcutaneous injection.14 Only two natural sources of penicillins were 
known from the time of their discovery, namely penicillin G and penicillin V.15 However, after 
the enzymatic hydrolysis of the C6 amido side chain of penicillins was achieved, numerous 
semi-synthetic derivatives were synthesized from 6-aminopenicillanic acid (6-APA) by 
acylation (Figure 1.4).13 Natural penicillin G and V showed activity only against Gram-positive 
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bacteria. Later, semi-synthetic derivatives such as ampicillin and amoxicillin were found to be 
effective against both Gram-positive and Gram-negative bacteria.16 Semi-synthetic penicillins 
have been used widely since World War-II to treat bacterial infections.17 To this day, the semi-
synthetic penicillin amoxicillin, manufactured by GlaxoSmithKline, is still used widely to treat 
bacterial infections.18 Novel penicillin agents are still being developed; however, the main 
topic of interest in this study is the cephalosporin class of -lactam antibiotics, which are 
discussed briefly in next section. 
 
Figure 1.4: Timeline for evolution of penicillin derivatives.13   
 
1.2.1  Cephalosporins 
 In 1945, many people suffered from an epidemic of typhoid fever caused by the Gram-
negative bacterium Salmonella enterica.16 Giuseppe Brotzu, an Italian pharmacologist, isolated 
a fungus from sewage water.19 This fungus was later named Cephalosporium acremonium. The 
fungal broth was found to inhibit certain Gram-negative bacteria including Salmonella typhi, S. 
paratyphi B, Yersinia pestis, Brucella melitensis, Vibrio cholera and Staphylococcus 
aureus.16,10 Three different compounds were isolated from Cephalosporium acremonium, 
namely cephalosporin P, cephalosporin N (penicillin N) and cephalosporin C. Cephalosporin C 
showed significantly higher antibacterial activity amongst them. Its structure was determined 
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(Figure 1.5) by E. P Abraham and G. C. F Newton in 1961.19,20 All cephalosporins incorporate 
a β-lactam ring that is fused with a dihydrothiazine ring. Cephalosporin C on acidic treatment 
gave 7-amino cephalosporonic acid (7-ACA), which is a key precursor for the synthesis of 
major cephalosporins available in today’s market (Figure 1.5).20 
 
Figure 1.5: Cephalosporin C and 7-Aminocephalosporanic acid (7-ACA) respectively. 
 Due to the potent antibacterial activity of cephalosporins, researchers began to study 
and develop derivatives with a cephalosporin core structure. Cephalosporins have been 
classified into five generations.21 The classification is based on their activity towards Gram-
positive and Gram-negative bacteria. However, the basis of their classification is often 
imprecise.  
 The first generation cephalosporins (Figure 1.6) show activities against most of the 
Gram-positive bacteria including methicillin-susceptible Staphylococci and non-enterococcal 
Streptococci. After the emergence of methicillin-resistant Staphylococcus aureus (MRSA) 
pathogens the first generation cephalosporins were used as first-line agents.  
 
Figure 1.6: Examples of first generation cephalosporins. 
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 The second generation cephalosporins (Figure 1.7) show high activities against Gram-
negative bacteria such as Haemophilus influenzae and Enterobacter aerogenes. In addition, 
second generation cephalosporins also possess some activity against Gram-positive bacteria. 
Cefuroxime amongst them could penetrate the blood brain barrier (BBB),  and hence was used 
to treat meningitis.10  
2
2
2
2
2
2
 
Figure 1.7: Examples of second generation cephalosporins. 
 The third generation cephalosporins (Figure 1.8) show broad spectrum activities against 
both Gram-negative as well as Gram-positive bacteria. These derivatives are less susceptible to 
hydrolysis by β-lactamases (later discussed briefly in section 1.3.1).  
2
2
2
2
2
2
 
Figure 1.8: Examples of third generation cephalosporins. 
 Third generation cephalosporins were mainly used to treat hospital-acquired and 
community-acquired infections. Many compounds from this generation were also able to 
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penetrate the blood brain barrier (BBB) and were used to treat meningitis caused by 
Pneumococci, Meningococci, Haemophilus influenza, Klebsiella and penicillin-resistant 
Neisseria gonorrhoeae.10 
 The fourth generation cephalosporins (Figure 1.9) demonstrated extended spectrum 
activities against Enterobacter spp., Citrobacter freundii and Serratia marcescens. 
Unfortunately, these drugs were not effective against Gram-positive bacteria which were 
already resistant to other β-lactams.10  
 
Figure 1.9: Examples of fourth generation cephalosporins. 
 The fifth generation cephalosporins (Figure 1.10) were developed in the last decade and 
are still under research and clinical trials. These antibiotics show activity against multidrug-
resistant S. aureus, such as: MRSA, VISA (Vancomycin-intermediate S. aureus), Vancomycin-
resistant S. aureus and certain S. pneumoniae.22 
 
Figure 1.10: Examples of fifth generation cephalosporins. 
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1.3 Bacterial Resistance to -lactam Antibiotics 
 Widespread use and abuse of antibacterial compounds has led to antibiotic-resistant 
strains of Gram-positive and Gram-negative bacteria.8,23 Bacterial resistance against -lactam 
antibiotics occurs via four major pathways which include: production of β-lactamase enzymes, 
that cleave the key -lactam ring of the -lactam antibiotics hydrolytically, and which are the 
focus of this research;  modification of the antibiotic target site, in which the binding target site 
of antibiotics penicillin binding protein (PBP) is altered in most resistant bacterial pathogens; 
expression of efflux pumps, which decrease the efflux for the drugs through the cell surface; 
and decreased expression of outer membrane proteins (OMPs), that are responsible for uptake 
of the drugs into the bacterial cell.24,25 Among these resistance mechanisms, the production of 
-lactamase enzymes is one of the major pathways and is discussed briefly in section 1.3.1. In 
order to explore the solution to bacterial resistance process; firstly, it is important to have an 
insight into the mode of action for -lactam antibiotics. 
 The bacterial cell wall is made up of a tightly cross-linked peptidoglycan layer that 
maintains the cell rigidity, shape and protects it against environmental threats.26 The bacterial 
cell comprises of a cross-linked cell wall, which is made by cell wall transpeptidase enzymes.27 
They are commonly known as penicillin binding proteins (PBPs).28 These enzymes are 
responsible for the formation of the basic repeating units of N-acetyl glucosamine (NAG) and 
N-acetyl muramic acid (NAM) cross linked with each other by D-alanine-D-alanine amide 
bonds.26 Figure 1.11 represents the cross linking process in E. coli and S. aureus cell walls.29–31  
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Figure 1.11: Cross linkage by D-Ala-D-Ala transpeptidase in [A] E. Coli and [B] S. aureus. 
(DAP = diaminopimelic acid; Glx = Gln or Glu; NAG = N-acetyl glucosamine; NAM = N-
acetyl muramic acid).29 
 Tipper and Strominger in 1965 proposed a mechanism based on an analogy between the 
structure of penicillin and the D-Ala-D-Ala part of the trans peptidation process in formation of 
the peptidoglycan cell wall (Figure 1.12).31  
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Figure 1.12: Conformational similarity between penicillin and D-Ala-D-Ala.31 
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 As a result of the structural similarity of the β-lactam and of the D-Ala-D-Ala, the 
antibiotic forms a covalent penicilloyl-enzyme complex with the transpeptidase that is 
responsible for cell wall cross binding. The acyl enzyme complex hydrolyses very slowly (or 
not at all) to generate the free transpeptidase enzyme (Figure 1.12). The acyl enzyme linkage 
leads to the inhibition of bacterial transpeptidase enzyme which prevents completion of cell 
wall synthesis. Since the rigid cell wall is incomplete, the cell contents are subjected to severe 
osmotic pressure and eventually burst.26 
 
1.3.1  Resistance caused by -lactamases 
 The existence of resistance to -lactam antibiotics was first observed by Abraham and 
Chain in 1940, who reported that some strains of Staphylococci developed resistance against 
benzylpenicillin.32 With the clinical use of synthetic cephalosporins, resistance shown by 
Gram-positive organisms was decreased.21 Gram-negative organisms, on the other hand started 
to develop resistance against almost all β-lactam antibiotics.33 
  Approximately 900 β-lactamase enzymes have been reported.34 In the early stage of β-
lactam antibiotic development, β-lactamases were divided into classes depending on their 
response to antisera, their substrate profile and on the plasmid-mediated enzymes that can be 
distinguished by isoelectric focusing. β-Lactamases were grouped into two classes,35 namely 
Cephalosporinases (rapidly hydrolyze cephalosporins) and Penicillinases (rapidly hydrolyze 
penicillins). 
 Presently, the classification of β-lactamase is based on amino acid residues in the active 
site. The β-lactamases were classified into two major groups depending on their amino acid 
residues found in the active site, namely serine -lactamase (SBLs) and metallo -lactamase 
11 
 
 
(MBLs). A proposed mechanism for the hydrolysis of -lactam antibiotics by serine -
lactamases (SBLs) and metallo -lactamases (MBLs) is shown in figure 1.13.  
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Figure 1.13: Proposed mechanism for the hydrolysis of -lactam antibiotics.  
 In SBLs, the serine bound hydroxide ion attack the -lactam bond; forming a 
tetrahedral intermediate which then forms a acyl enzyme complex. In presence of water in the 
active site, very fast hydrolysis would generate the penicilloic acid. In MBLs, the zinc bound 
hydroxide anion attacks the -lactam bond; forming the tetrahedral intermediate which then 
undergoes hydrolysis in presence of water to give penicilloic acid. The SBLs and MBLs have 
been sub-classified into the following four sub-groups:35–37 
 [i]  Class A β-lactamases 
 The enzyme active site of class A β-lactamases contains a serine residue, that acts as a 
nucleophile and contains a glutamate residue (Glu166) which acts as a general base in the 
catalysis. The most common class A β-lactamases are TEM, SHV, and CTX-M. They are 
resistant to penicillin derivatives and hydrolyze them easily when compared to cephalosporins 
and carbapenems (Figure 1.14).35–37 
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Figure 1.14: Clinically used and under clinical trial serine-β-lactamase inhibitors. 
[ii]  Class B β-lactamases  
 These enzymes use Zn2+-bound water or hydroxide to hydrolyze the β-lactam 
antibiotics. The most wide-spread clinical threat is from IMP, VIM, SPM and NDM enzymes. 
Even though the metal ion chelators such as EDTA and dipicolinic acid can act as the 
corresponding inhibitory agents for class B β-lactamase, they are not selective and so are not 
suitable for clinical use. Therefore, there is an urgent need to develop class B β-lactamase 
inhibitors.35–37 
[iii]  Class C β-lactamases  
 This class was identified after class A -lactamases in which it incorporates a tyrosine 
phenolate anion as a general base in catalysis. The class C AmpC lactamase is resistant to 
clavulanic acid and also to cephalosporin candidates. 35–37 
[iv]  Class D β-lactamases 
 -Lactamases in this group were observed to hydrolyze oxacillin derivatives 
particularly well. Therefore, they are also known as OXA enzymes. These were also identified 
as serine-containing enzymes that are usually found in P. aeruginosa, Acinetobacter baumannii 
and Enterobacteriaceae. They incorporate a lysine residue that reacts with CO2 to form a 
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carbamate anion that acts as a general base during hydrolysis. Class D β-lactamases are 
inhibited by certain cephalosporin derivatives.35–37 
 As a result of the resistance of bacteria against -lactam antibiotics, combination 
therapies involving the antibiotic and a β-lactamase inhibitor were developed to fight the 
resistance caused by ESBLs.10 For instance, the combination therapy of ceftaroline fosamil 
(prodrug) and avibactam (non β-lactam β-lactamase inhibitor) was studied for phase-II clinical 
trials (Figure 1.15).22 Cefotaxime and ceftazidime from the fourth generation of cephalosporin 
were studied for the combination therapy with β-lactamase inhibitors and prominent increase in 
antibiotic activity was observed against the resistant strains.10 
 
Figure 1.15: The combination therapy of cephalosporin and avibactam.22 
 Cephalosporin antibiotics are still being researched and novel cephalosporin derivatives 
are being developed that have the potential ability to act both as -lactam antibiotics as well as 
-lactamase inhibitors. For example, Cubist Pharmaceuticals is currently developing 
ceftolozane – tazobactam combination under phase-III clinical trials, which has improved 
activity versus P. aeruginosa and other Gram-negative bacteria (Figure 1.16).38 Other 
pharmaceutical companies have also reported exploring new cephalosporin analogues 
including Shionogi & Co. Ltd., that is developing a cephalosporin called S-649266.39 It has 
been reported that this cephalosporin is 10-10,000 times less susceptible to carbapenemase than 
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ceftazidime, cefepime and meropenem.39 Unfortunately, the structure of S-649266 has yet to be 
disclosed.   
 
Figure 1.16: The combination therapy of ceftolozane and Tazobactam.38 
 At the University of Waterloo, the Dmitrienko group is developing novel cephalosporin 
derivatives which have the potential to act as metallo -lactamase (MBLs) inhibitors. For 
example, cephalosporin analogues having a benzoylthio group at C3ʹ of a cephalosporin core 
structure have been developed (Figure 1.17).34  
 
Figure 1.17: Novel cephalosporin derivative as β-lactamase inhibitors (Dmitrienko group).34 
 A possible mechanism was proposed for these C3ʹ- benzoylthio compounds acting as 
metallo-β-lactamase inhibitors shown in figure 1.18. The proposed mechanism suggests that 
after β-lactam hydrolysis by the metallo β-lactamase enzyme the benzoylthio anion acts as a 
good leaving group creating an intermediate 1.5 that binds tightly to the zinc inons in the active 
site of the MBLs. Enzyme assay of these potential compounds were also studied against 
MBLs, and the corresponding IC50 values are shown in Table 1.1.34  However, modifications at 
the R group (Figure 1.17) are currently under investigation. Extensive microbiological 
experiments by the Dmitrienko group have demonstrated that compounds of this type are 
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capable of acting in synergy with β-lactam antibiotics (e.g. meropenem Figure 1.19) resulting 
in a decrease in the minimum inhibitory concentration (MIC) of the antibiotic when the 
inhibitor and antibiotic are used in combination against resistant bacteria (e.g Pseudomonas 
aeruginosa) that produce MBLs (VIM-2). 
 
Figure 1.18: Mechanism for inhibition of metallo β-lactamases (MBLs).34 
Table 1.1: IC50 values for some C3ʹ- thiobenzoyl cephalosporin derivatives showing inhibitory 
activity against MBLs in vitro.34 
Class B 
IMP-1 
Class B 
VIM-2 
R=  
 
3.1 µM 
 
1.8 µM 
R=  
 
8.2 µM 
 
4.2 µM 
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Figure 1.19: Chemical structure of meropenem. 
 Optimization of the potency of the inhibitors is underway in the Dmitrienko group. 
Once a compound with sufficient potency against MBL producing P. aeruginosa is achieved, 
the next phase of the drug development process will involve preliminary pharmacokinetic (PK) 
studies in mice. The animal studies will be carried at the Preclinical Drug Research Consortium 
(Vancouver, BC). Analysis of the concentration of the drug in serum samples will, however, be 
carried out in the Dmitrienko laboratory. This requires that an analytical method with the 
appropriate internal standards be developed, which is the overall goal of this research project. 
 
1.4  Pharmacokinetic Parameters 
 Pharmacokinetic/Pharmacodynamics (PK/PD) studies are typically conducted during 
preclinical trial and clinical trial lasting up to phase-III for drug candidates.40 The 
pharmacokinetic analysis provides insight into the time course of drug absorption, distribution, 
metabolism and excretion (ADME).41,42 These PK/PD parameters are studied using various 
mathematical models, linear and non-linear equations, compartment models and statistical 
calculations.41 
 The therapeutic efficacy of antibiotics directly correlates to the time for which the 
antibiotic is above the minimum inhibitory concentration (T> MIC).43 Although, the -lactam 
antibiotics are the first line of treatment for bacterial infection in critically ill patients, their 
efficacy is difficult to evaluate.41 Most -lactam antibiotics are available via the parenteral 
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route and the oral route depending on their pharmacodynamics parameters.44 The 
bioavailability of -lactam antibiotics is dependent on their half-life (t1/2) and their serum 
concentration.41 The pharmacokinetic behavior of these compounds is observed to follow a 
linear kinetic relation, in which the rate of reaction is directly proportional to the concentration 
of the drug.43  
 PK parameters are dependent on the type of the compartment model being considered. 
In a non-compartment modeling the whole body is considered to be one system. Non-
compartment models are constructed for intravenous infusion (I.V.) of most cephalosporins 
during their preclinical studies.42 The plasma drug concentration versus time profile is one of 
the most important PK parameters and is determined by measuring the drug concentration in 
plasma at various time intervals after dosing. A typical PK graph is constructed based on this 
data. Various PK parameters are determined from this information using mathematical 
formulas and statistical calculations44 such as:  
 Peak plasma concentration (Cmax) in which the time corresponding to maximum drug 
concentration in plasma is determined. At this point of time, the rate of drug absorption 
is equivalent to the rate of drug elimination.21,40,41 
 Time of peak concentration (tmax) which is the time at which the concentration of the 
drug in plasma achieves at its peak.21,40,41 
 Area under curve (AUC) - The total integrated area under the plasma level versus time 
profile is known as the Area under the Curve (AUC). This value is used to determine 
the total amount of drug that is present in systemic circulation after dosing.21,40,41  
 Apparent volume of distribution - The hypothetical volume of body fluid into which the 
drug is dissolved or distributed is termed as apparent volume, and a constant relation 
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between the concentration of drug in plasma and amount of drug in blood is 
proportional and represented by apparent volume of distribution.21,40,41 
 Clearance (Cl) and Renal Clearance (ClR) - The hypothetical volume of body fluid 
containing drug from which the drug is cleared completely in a specific time period is 
called the clearance rate. The volume of blood or plasma completely cleared of the 
unchanged form of drug by the renal route per unit time is called renal clearance.21,40,41  
 Half-life (t1/2) - The time period required for the concentration of drug to decrease by 
one half is called the half-life.21,40,41 
 Determination of all the above mentioned pharmacokinetic parameters provides 
information about the behaviour of all therapeutic agents. The plasma concentration 
measurements are very useful to know the absorption behaviour of the drug, as well as its 
distribution in the body.45 This helps to determine the therapeutic window. PK parameters are 
extremely important to decide the safe dose of new drugs. A Preclinical PK study provides an 
insight about the behaviour of new drugs during their clinical trial. A large number of 
compounds showing good activity in vitro are rejected in their clinical trials because their PK 
studies show that they do not possess adequate bioavailability of the drug or that they exhibit 
various types of toxicity. Thus, a PK study helps to optimize the lead compounds and is 
essential to select a new drug whose PK behaviour is within the therapeutic window.40 
 Most initial PK/PD studies are carried out in mice. To construct an accurate plasma 
drug concentration versus time profile, blood samples are collected at intervals before and after 
the dose administration of compounds which are evaluated for its PK parameters. The plasma 
is centrifuged and all the biomolecules are extracted using an organic solvent.42 The organic 
phase is separated and the aqueous phase is dried and analyzed through liquid chromatography-
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tandem mass spectrometry (LC/MS) assays. The analyte sample is mixed with an internal 
standard of known concentration. The concentration of analyte is measured from the relative 
concentration of internal standard from its mass spectrometry analysis. For example, in a 
pharmacokinetic study of an intravenous ceftolozane-tazobactam combination (single and 
multiple dose), plasma samples were collected before dosing at 30, 60, 65, 75, and 90 min and 
after dosing at 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours.38 These samples were analyzed using 
LC/MS assays and a plasma drug concentration versus time profile was generated. All of the 
rest of the PK parameters are calculated from the plot of plasma drug concentration vs time 
profile by using WinNonlin software.38   
 Accurate determination of PK parameters is very crucial in the process of drug 
development.41 Over the last decades much research has been conducted to acquire higher 
accuracy in these PK studies. A brief description of LC/MS and internal standards is provided 
in the next few sections. To conduct accurate PK studies it was very important to use internal 
standards which very closely resemble the analyte which is being tested.46 The present thesis 
focuses on the development of these internal standards to conduct PK studies of a wide range 
of novel cephalosporin analogues which are in the pipeline of drug development. 
 
1.5  Chromatography 
 Various forms of chromatography are used widely for purification and separation of 
small organic molecules which are structurally closely related.47 Chromatographic techniques 
work on similar principles, in which the compounds in a mixture are distributed between a 
stationary phase and mobile phase.48 The mobile phase runs in one direction and the 
compounds are separated as a result of their different rates of travel, which are determined by 
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their relative affinities for the mobile phase and the stationary phase.47 Amongst all the 
chromatographic techniques high performance liquid chromatography (HPLC) is one of the 
most widely used methods. A more recent variant, ultra-performance liquid chromatography 
(UPLC) is now being widely used to conduct major analytical studies in the field of drug 
discovery.49 
 Mass spectrometry is an analytical technique in which small organic molecules are 
analyzed based on the mass-charge ratio.50 Over the last few decades there has been an 
enormous development in this field. In the 1980s, John Fenn (Nobel laureate) discovered the 
electrospray ionization method which changed the whole scenario of mass spectrometric 
studies. Since then, mass spectrometers have been widely used in clinical laboratories and the 
pharmaceutical industry as a reliable analytical technique for compound identification and 
quantitative studies.50 In order to perform mass spectrometric studies the sample to be analyzed 
is first prepared by mixing with suitable solvents. The compound is ionized using various 
ionization techniques. After the ionization of the compound, the ions are separated based on 
their mass to charge ratio. These ions further pass through the analyzer and are then detected 
with the help of a computer device. A typical MS graph shows the plot of mass to charge ratio 
(m/z) to its relative abundance.47  
 Hyphenated analytical techniques were discovered which showed more specificity and 
robustness. Gas Chromatography Mass spectrometry (GC-MS) and Liquid Chromatography 
Mass spectrometry (LC-MS) are widely used today for high throughput screening, selectivity, 
specificity and quantitative analysis of small organic molecules. Apart from simple organic 
molecules, MS is also used widely to analyze peptides, carbohydrates and a wide range of 
natural products. Owing to the nature of these compounds, especially biological species, which 
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cannot be vaporized for ionization in the gas phase, LC-MS is much preferred method for their 
analysis compared to GC-MS.50 LC-MS plays an important role in the accurate determination 
of drug concentration in plasma.  
 In LC-MS the basic working principles of both the above mentioned analytical 
techniques are combined. The mixture of closely related compounds is injected on the 
chromatographic column.49 Here the analyte is run through with a compatible mixture of 
mobile phase and separated. The solution is directly passed to the ionization chamber of the 
MS. After ionization, the ions are detected which helps to quantitate the analyte and analyse it. 
LC-MS has a wide application for the determination of PK parameters as mentioned earlier. 
After the collection of plasma samples during their pre-clinical and clinical studies, the analyte 
is extracted from plasma. In order to determine the drug concentration present at that particular 
time, a known amount of internal standard, which very closely resembles the analyte is mixed 
with it.51 Most commonly, a known amount of isotopically-labelled compound is mixed with 
an unknown amount of unlabelled analyte of interest. This mixture is loaded on the 
chromatographic column. Since, the internal standard and analyte only differ isotopically, they 
cannot be separated. Once the peak for the analyte is observed, the mobile phase is introduced 
into the ionization chamber with the help of an automatic sample injector. The ions travel in a 
vacuum tube depending on their charge to mass ratio. Further, they are analyzed and reported 
in the mass spectrum.47 Quantification of unlabelled compound can be carried out using the 
concentration of labelled compound. In this manner the plasma drug concentration is 
determined.52  
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1.6  Internal Standard 
 An internal standard is used during the quantification of analyte using mass 
spectrometry studies. HPLC and MS/MS (LC-MS/MS) are the most common and extensively 
used analytical techniques for measuring concentration of drug present in plasma, blood and 
urine samples. The internal standard is used as a reference substance to quantify the 
concentration of unknown analyte in these assays.53,54 The choice of an internal standard is 
very important for accurate quantitative analysis of an analyte. The choice of internal standard 
(IS) is based on several considerations: IS can never be found in the untreated sample, which 
would result in inaccuracy; IS should always be available in pure form and should be 
extremely stable throughout the reaction; ideally IS should be identical to the analyte and 
differs only in isotopic composition or structurally similar to the analyte and is eluted after the 
analyte.54 
 The best internal standard is an isotope labelled analogue of the analyte, which needs to 
be quantified. The isotope-labeled internal standards have the same chemical structure as the 
analyte, only differing in their atomic mass unit (amu) due to highly enriched presence of a 
particular isotope. HPLC and MS/MS techniques are respectively used for purification of the 
analyte and detection of its mass for quantitative analysis.55 Owing to structural identity, the 
analyte and its internal standard show the same retention time on the UPLC.53 However, these 
are differentiated by their mass analysis giving selective, specific and quantitative results.54 A 
known concentration of the isotope labeled compound is mixed in the plasma extract and the 
ratio of labeled to unlabeled analyte is determined using MS assay.56 It is very important to 
check the purity of internal standard prior to its use.56 Certainly, a little contamination in the 
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internal standard would lead to error in all the following results and hence would compromise 
the accuracy, reproducibility and robustness of the method.  
 
1.7  Isotope Labeling 
 Synthesis of a stable isotope-labeled compound for its use as internal standard can be 
time consuming and costly. Stable isotopes of hydrogen (2H/D), carbon (13C), nitrogen (15N), 
and oxygen (17O, 18O) are commonly available. However, the most cheap and easy method for 
synthesis of internal standard is by deuterium isotope labeling. Deuterium (D or 2H) is a stable 
isotope of hydrogen having 1 atomic mass unit (amu) more compared to protium (H), which is 
the most abundant isotope of hydrogen. Deuterium has been used extensively for various 
studies, which includes metabolic studies for organic compounds and analytical assay using 
LC-MS/MS and GC-MS/MS techniques.57 It is also useful for studies related to mechanism 
elucidation involved in enzymatic or chemical reactions.58  
 Costand timeeffective reactions involving H/D (Hydrogen/Deuterium) exchange 
have been extensively studied.59 Various approaches can be used that include pH-dependent 
exchange, exchange without the addition of acidic or basic deuterium source (these reactions 
might be applied for deuteration of the cephalosporin core), homogeneous metal catalysis, 
heterogeneous metal catalysis (e.g. palladium/carbon, platinum/carbon, rhodium/carbon and 
nickel/carbon). However, homogeneous and heterogeneous metal catalysis reactions are not 
applicable to label the core cephalosporin structure due to its instability under such conditions, 
since the β-lactam ring can hydrolyze at high temperature and pressure.59  
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1.8  Hypothesis and Rationale 
 Examination of the literature concerning deuterated analogues of cephalosporins reveals 
that the most common approach involves introduction of three or more deuterium atoms into 
one of the side chains R1 or R2 attached to the cephalosporin core ring structure (Figure 1.20).  
 
Figure 1.20: General cephalosporin structure.  
 For example, Figure 1.21 illustrates a few examples of cephalosporins deuterated on 
their side chains along with the supplier and its cost. In all the examples, the deuterium was 
incorporated on the C7 side chain.  
 
Figure 1.21: Commercially available deuterated cephalosporin analogues. 
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 The presence of an alkoxyimino group on the C7 side chain of cephalosporin is found 
to be beneficial for binding to PBPs. One strategy to develop novel cephalosporin antibiotics 
involves modification of the alkoxyimino group. According to the current pharmaceutical and 
academic research, internal standards used for the assay of these cephalosporins are 
compounds in which this alkoxyimino side chain is isotopically labeled. This necessitates the 
task of preparing a standard for each promising candidate, labelled by a different synthetic 
approach. 
 Since it was proposed that in the present study, it would be possible to carry out 
preliminary PK/PD studies on several cephalosporin-type MBLs inhibitor, placing the 
deuterium isotopes in new side chains R1 and R2 (Figure 1.20) might require the development 
of several isotope labeling strategies. It occurred to this group that the PK/PD studies could be 
facilitated by having access to a cephalosporin intermediate in which the deuterium isotopes 
were incorporated in the core ring structure, since R1 and R2 could then be varied without the 
need to design new methods for deuteration. It was also thought that such a deuterated 
cephalosporin core structure could be of value to others who are involved in the discovery and 
development of novel cephalosporins with improved antibacterial potency. 
 Thus, this thesis aims to synthesize a core cephalosporin analogue multiply deuterated 
at two sites. The availability of a multiply deuterated core cephalosporin compound will 
facilitate screening of cephalosporin derivatives modified on the C7 and C3 side chains. In 
order to avoid peak overlap during quantitative analysis using mass spectrometry, a minimum 
of three deuteriums should be present in the internal standard. The analyte may include 
hydrogen, carbon, nitrogen, sulphur, oxygen, halogens etc. As a consequence of the existence 
of minor isotopes at natural abundance, molecules show not only molecular ion peak [M]+ but 
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also [M+1]+ and [M+2]+ peaks. [M+1]+ peak arise from the 1.11% 13C, 0.38% 15N, 0.78% 33S, 
0.016% 2H and to a lesser extent 0.04% 17O present among the sample molecules. The [M+2]+ 
peak arises from the 4.4% 34S, 0.2% 18O and 32.5% 37Cl (if present). In order to avoid any peak 
interference between the analyte and internal standard peaks, having three or more atomic mass 
units higher in internal standard compared to the analyte will be observed distinct from that of 
the analyte. The peaks for internal standard can then be differentiated from the analyte and 
hence an accurate concentration of the drug at that time point can be measured without 
interference from the analyte MS peaks due to its isotopes at natural abundance.  
 The primary objective of this study is to synthesize a multiply deuterated core 
cephalosporin compound. The core structure of the cephalosporins has hydrogens at C2, C3ʹ, 
C6 and C7. The literature review discussed in Chapter 2 suggests that H/D exchange reactions 
have been accomplished on one of the methyl group at C2 of a penicillin sulfoxide60 and 
cephalosporin sulfoxide61,62 at the C2 position. Replacing the hydrogen with deuteration at C7 
was a very time consuming exercise as mentioned by Baldwin and his co-workers.63 No reports 
of incorporation of deuterium at C3ʹ or C6 of the cephalosporin core were found.  
 In this thesis research C2 and C3ʹ were considered as the sites for deuteration, as shown 
in Figure 1.22.  
 
Figure 1.22: Proposed sites of deuteration in the core cephalosporin structure.  
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Chapter 2 
Literature Review 
 
2.1  Previous work done to Synthesize Core Deuterated Cephalosporins 
 Cooper and co-workers, while studying the penicillin sulfoxide-sulfenic acid 
equilibrium, studies carried out deuterium incorporation at the methyl group of a penicillin 
sulfoxide by refluxing the sulfoxide of penicillin V in a mixture of benzene and D2O. This 
reaction involves a β-elimination reaction to produce the sulfenic acid/alkene, and then 
deuterium exchange to generate the O-deuterated sulfenic acid. This then undergoes reversal of 
the elimination reaction as shown in Scheme 2.1.60 
 
Scheme 2.1: The mechanism proposed by Cooper and co-workers for the deuteration of 
penicillin V sulfoxide.60 
 Scheme 2.2 illustrates the reaction conditions mentioned for performing H/D exchange. 
Benzene acts as a solvent for this reaction and D2O is the source of deuterium incorporation at 
the methyl side chain. Compound 2.1 was stirred with a solution of benzene and D2O at 80 C 
for 24 hours to give compound 2.2. The experimental detail related to the reaction was not 
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mentioned. However, the authors reported the recovery of penicillin sulfoxide 2.2 after the 
reaction as 100% and its 1H-NMR study showed an average of one deuterium atom located 
only at its -methyl group. Mass spectrometry analysis showed a mixture of 45% d0, 43% d1, 
11% d2, and 1% d3 products. 
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Scheme 2.2: Synthesis of C-2 deuterated penicillin V sulfoxide.60 
 Taiichirou and his co-workers in 1981, were the first researchers to perform H/D 
exchange at the C2 position of a cephalosporin core.62 However, no supporting information 
was given regarding the experimental conditions and the amount/percent of deuterium present 
at C2.  
 
Scheme 2.3: H/D exchange at C2 of cephalosporins by Taiichirou and co-workers.62 
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 Scheme 2.3 illustrates their reaction scheme in which compound 2.3 was oxidized to 
sulfoxide 2.4 using m-CPBA. The H/D exchange was carried out by refluxing compound 2.4 
with MeOD for 2 hours to give compound 2.5. This was then reduced back to the sulfide 2.6 
using acetyl chloride in the presence of potassium iodide and DMF as solvent.   
 Later, Richter and his co-workers in 1990 performed a similar H/D exchange using 
DMSO-d6 and methanol-d4.61 The experiment was performed to study the 2-3 isomerization 
of a cephalosporin ester. When a cephalosporin ester (prodrug) is administered by an IV 
infusion route, it undergoes 2-3 isomerization due to the presence of base in blood plasma. 
The researcher aimed to study the kinetic rate constants for the isomerization process. 
However, to our interest they carried out H/D exchange on C2 of a core cephalosporin 
analogue. The experimental procedure was not mentioned in detail. Their NMR studies show 
presence of 70% deuterium at C2 of the cephalosporin core.61  
 
Scheme 2.4: H/D exchange on C2 of cephalosporins by Richter and co-workers.61 
 Scheme 2.4 illustrates their reaction scheme in which compound 2.7 was oxidized to 
sulfoxide 2.8 using m-CPBA. The H/D exchange was carried out by heating compound 2.8 
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with methanol-d4 and DMSO-d6 at 50 C for 90 minutes. Then the solvent was evaporated 
under reduced pressure and fresh methanol-d4 was added and the reaction was repeated for 90 
minutes to give compound 2.9. The authors reported 70% of deuterium incorporation at C2 
according to NMR studies. Compound 2.9 was reduced back to the sulfide 2.10 using acetyl 
chloride in the presence of sodium iodide and DMF as solvent.   
 Incorporation of tritium (3H/T) at C7 of a cephalosporin analogue was carried out by 
Baldwin and co-workers as illustrated in Scheme 2.563 where compound 2.11 was the starting 
material. This was converted into the Schiff base 2.12 after several steps, which was then 
oxidized using lead oxide to give compound 2.13. Compound 2.13 was reduced to the C7 
tritiated Schiff base 2.14 using sodium borotritide which was then subjected to hydrolysis 
giving compound 2.15 as the free amine with an overall yield of 21%.   
 
Scheme 2.5: Tritium (3H/T) incorporation at C7 of cephalosporin analogue (* Tritiated).63 
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2.2  Objectives 
 As mentioned previously in section 1.8, deuteration at C2 and C3ʹ was proposed to be 
carried out to synthesize the desired multiply deuterated analogue as shown in Figure 1.22. 
Therefore the primary objectives assigned for the present thesis were as follows: 
1. To perform H/D exchange at C2 of the core cephalosporin system using various 
approaches. 
2. To incorporate deuterium at C3ʹ of the core cephalosporin system using various 
approaches.  
3. After the completion of objective 1 and 2, both the strategies would be combined on 
one molecule to synthesize a core trideuterated cephalosporin analogue.  
 The deuterated core structure could then be used to synthesize isotopically labeled 
versions of cephalosporin derivatives. The synthesized internal standards might be used in 
future to determine the PK parameters for cephalosporins using HPLC and MS/MS assay.  
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Chapter 3 
Results and Discussion 
 The main goal of this project is to synthesize a core-trideuterated cephalosporin. The 
core deuterated cephalosporin can be used to synthesize various internal standards for 
compounds of interest with modified C3ʹ and C7 side chains (Figure 1.22) 
 
Figure 1.22: Proposed sites of deuteration in the core cephalosporin structure.  
 Due to the increase in antibiotic resistance, more research is being conducted to develop 
novel cephalosporins acting as -lactamase inhibitors and as antibiotics. It is challenging to 
synthesize internal standards for each new modification on the side chains of cephalosporins. 
Hence, this project will be useful to synthesize internal standards for a wide range of novel 
cephalosporin compounds with modification on their side chains using the core trideuterated 
cephalosporin compound. The objectives set for this project are to perform H/D exchange on 
C2 and deuterium incorporation at C3ʹ using various approaches and then to combine the two 
methods to produce a trideuterated cephalosporin core compound.  
 
3.1  Objective 1: Hydrogen/Deuterium (H/D) Exchange at C2 of Cephalosporins  
 Our initial thoughts on the H/D exchange were based on the potential acidity of the 
hydrogens at C2 and C3’. Since the hydrogens at C2 and C3ʹ of the cephalosporin system are  
to the -unsaturated ester, they are expected to be weakly acidic and might potentially 
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undergo de-protonation to form a conjugated dienolate which upon re-protonation by a weak 
deuterated protic acid would result in deuterium incorporation. A potential mechanism for 
deuteration at C2 and C3ʹ is proposed. Scheme 3.1 illustrates that the H/D exchange on C2 
initiated with the non-deuterated base, deprotonating at C2 followed by deuteration using 
deuterated protic acid. This exchange is proposed to continue until it reaches an equilibrium 
stage. Scheme 3.2 represents the similar proposed mechanism of deuteration at C3ʹ.  
 
Scheme 3.1: Proposed mechanism for base-catalyzed H/D exchange at C2. 
 
Scheme 3.2: Proposed mechanism for base-catalyzed H/D exchange at C3ʹ. 
 In cephalosporin esters, base catalyzed dienolate formation will compete with an 
isomerization reaction yielding a mixture of 2 and 3 isomers as shown in Scheme 3.3.64 It 
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has been documented that the 2 isomer shows no biological activity and is the unwanted 
isomer. 
 
Scheme 3.3: Isomerization observed for cephalosporin esters in presence of base.64  
 To convert the 2 isomer to the 3 isomer as shown in Scheme 3.4,65 the mixture of 2 
and 3 is stirred with an oxidizing agent (e.g. m-CPBA) to yield a sulfoxide for which the 2 
to 3 equilibrium is strongly favored in the direction of the 3 isomer. The sulfoxide can then 
be reduced back to sulfide using PCl3.66  
 
Scheme 3.4: A mixture of 2 and 3 cephalosporin isomers oxidized to corresponding 3 
sulfoxide and its subsequent reduction back to sulfide. 
 Thus, if deuterium incorporation were attempted at C2, the 3 to 2 isomerization 
might lead to complications. The experiments described below made use of cephalosporin 
sulfoxide to deal with the 2 to 3 isomerization issue.  
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3.1.1  H/D exchange at C2 of Cephalosporin Core using Benzene/D2O 
 One of the concerns about base-induced H/D exchange in the -lactam antibiotic series 
is the sensitivity of the -lactam ring towards nucleophilic attack. Thus, we sought out 
literature precedent for H/D exchange on -lactams. As indicated in Chapter 2, Cooper and co-
workers60 had effected an exchange of one of the methyl groups of a penicillin sulfoxide by 
heating in a mixture of deuterium oxide (D2O) and benzene without hydrolysis of the -lactam. 
This indicated that such conditions might also be compatible with the -lactam bond of 
cephalosporins. This led to experiments aimed to explore the synthesis of cephalosporin 
sulfoxide in order to make the hydrogens at C2 sufficiently more acidic so that they might 
undergo reversible de-protonation and deuteration in D2O under prolonged heating 
conditions.60 Thus, for the initial trial to verify the experimental conditions, the C3ʹ hydroxyl 
cephalosporin derivative 3.1 (obtained from Dr. Ahmad Ghavami, in this laboratory) was 
esterified at C3ʹ position using 4-chlorobenzoyl chloride, DMAP, and pyridine overnight at 
room temperature to give 3.2. It was believed that making an ester derivative would make the 
hydrogens at C3ʹ more acidic; therefore, there was a possibility of exchanging hydrogens at C2 
and C3ʹ in one step. In addition the free hydroxyl derivative 3.1 in presence of base is known to 
form C3ʹ lactone with the carboxylate at C4.67 The solution of 3.2 in DCM was then oxidized 
to the corresponding sulfoxide at 0 C, using m-CPBA to give 3.3.65 The H/D exchange 
reactions were carried out on 3.3 under various reaction conditions to give 3.4 as summarized 
in Table 3.1. 
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Scheme 3.5: H/D exchange using benzene and D2O. 
Table 3.1: Reaction conditions for H/D exchange to obtain 3.4 
Exp.  
No. 
Quantity of Reagent Time 
(h) 
(%D) by 1H NMR 
1. 3.3: 0.07 mmol; D2O: 0.1 mL (100 eq) 19 20% D at one prochiral H of C2 
2. 3.3: 0.07 mmol; D2O: 1 mL (1000 eq) 93 60% D at one prochiral H of C2 
3. 3.3: 0.15 mmol; D2O: 10 mL (10000 eq) 136 78% D at one prochiral H of C2 
 
 The deuteration of 3.3 at C2 was monitored by 1H NMR analysis. The first trial in the 
present thesis (entry 1) began by using 100 equivalents of D2O relative to 3.3 and refluxing for 
19 hours. The proton signal for each of the diastereotopic hydrogens at C2 is observed as a 
doublet. A decrease in the integration for one of these prochiral hydrogens was observed. 
However, the other doublet appears under the peak of hydrogens at C8 (phenyl-CH2 side 
chain). Therefore the amount of deuterium enrichment was measured depending on the relative 
integration of only one of the prochiral hydrogen peak at C2. From the relative integration of 
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protons in the 1H NMR spectrum, it was determined that there was 20% deuterium 
incorporation on one of the hydrogens at C2. In the next experiment (entry 2) in order to 
increase the deuteration on C2, the reaction mixture was allowed to stir for a longer period of 
time (93 hours). Also, the amount of D2O was increased to 1000 equivalents relative to 3.3, in 
order to favour greater deuterium incorporation at equilibrium. The 1H NMR suggests the 
exchange of 60% deuterium with one of the hydrogen at C2. Entry 3 in table 3.1 shows that the 
amount of D2O was increased from 1000 equivalents to 10,000 equivalents relative to 3.3 and 
the reaction time from 93 hours to 136 hours. 1H NMR integration confirmed 78% of 
deuterium was exchanged with one of the prochiral hydrogen at C2 (Appendix B; Figure 3.1). 
The doublet peak for another prochiral hydrogen at C2 showed interference with the peak of 
hydrogens at C8 (phenyl-CH2 side chain), therefore the deuterium enrichment cannot be 
measured with certainty. 
 Since this was the first set of reactions using these conditions, it was essential to 
conduct additional experiments for increasing the deuterium incorporation. Also, from the 
NMR spectroscopy studies there was no H/D exchange observed for the hydrogens at C3ʹ. 
Since C3ʹ acyl thio cephalosporin derivatives are an important focus of research in this group, 
an H/D exchange was attempted with such a derivative. After the first attempt of H/D 
exchange, similar reaction conditions were used to perform H/D exchange on C3ʹ thioester 
derivatives. Compound 3.5 was used as the starting material, which was commercially 
available. Under Finkelstein conditions, a suspension of 3.5 in acetone was stirred with sodium 
iodide at 0 C to synthesize the C3ʹ iodo derivative.34 The iodine was replaced in situ with 
thiobenzoate anion to yield 3.6 using sodium carbonate as base. Compound 3.6 was oxidized to 
give the sulfoxide 3.7 using m-CPBA at 0 C in 86% yield.65 H/D exchange on 3.7 using 
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benzene and D2O at 80 C for 154 hours afforded 3.8 with 28% deuterium incorporation at one 
of the C2 prochiral hydrogens as determined by 1H NMR spectroscopy (Scheme 3.6) 
(Appendix B; Figure 3.2). Again no H/D exchange was observed at C3ʹ of 3.8. It was decided 
that this approach to exchange was not ideal since it required prolonged reaction and only 
moderate levels of deuterium incorporation. 
 
Scheme 3.6: H/D exchange on 3.7 cephalosporin derivative. 
   
3.1.2  H/D Exchange at C2 of Cephalosporin Core using iPrONa/iPrOD 
 It was decided that a method of H/D exchange using a suitable base should be explored. 
Iwasaki et al. performed the deuteration of vitamin D3 via formation of its sulfone adduct using 
a base catalyzed H/D exchange reaction.68 Scheme 3.7 illustrates their work on base catalyzed 
H/D exchange in which the best result for the exchange was achieved using iPrONa/iPrOD and 
DMI (1,3-dimethyl-2-imidazolidinone) where DMI acts as a co-solvent, iPrOD is the source of 
deuterium and iPrONa acting as a base. The reaction was performed at 0 C. Since the base is 
somewhat sterically hindered it was felt that the reaction with the -lactam of a cephalosporin 
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might be slow at low temperature. Therefore, in this study the base catalyzed reaction was 
performed at 20 C. The reaction conditions used by Iwasaki et al. were similar to the 
proposed base catalyzed mechanism as mentioned previously in Schemes 3.1 and 3.2. 
Therefore, the same experimental condition was used on cephalosporin sulfoxide to check if 
the percentage of H/D exchange can be increased on C2. 
 
Scheme 3.7: H/D exchange on vitamin D3 by Iwasaki et al.68  
 Compound 3.5 was the best starting material, as it was readily and commercially 
available. A suspension of 3.5 was treated with m-CPBA at 0 C to give its corresponding 
sulfoxide 3.9.65 NMR studies indicated the presence of a mixture of 80% sulfoxide and 20% 
sulfone. The formation of the sulfoxide was very difficult to follow by TLC because the 
starting material 3.5 and 3.9 (sulfone) had the same Rf values. Without further purification the 
mixture was treated with iPrONa in a mixture of DMI and iPrOD. DMI was added as a co-
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solvent and iPrOD was added both as a solvent and deuterium source. iPrONa was synthesized 
insitu from the reaction of iPrOD and NaH. The reaction was carried out at 20 C as shown in 
Scheme 3.8. For all the experimental trials, one equivalent of iPrONa was used compared to 
compound 3.9. The difference in experimental conditions was for the reaction time which is 
summarized in table 3.2 to obtain deuterated sulfoxide 3.10. 
 
Scheme 3.8: Base catalyzed H/D exchange at C2 using iPrONa/iPrOD. 
Table 3.2: Reaction conditions for H/D exchange to obtain 3.10. 
Exp.  
No. 
Reaction conditions Time (h) (%D) by 1H NMR % 
yield 
1. 3.9 stirred with 
iPrONa/iPrOD (one  
equivalent) and DMI. 
1 40% D at one prochiral H of C2 70% 
2. 1.5 45% D at one prochiral H of C2 60% 
3. 2.0 50% D at one prochiral H of C2 60% 
 
 In the first attempt (entry 1), compound 3.9 was stirred with a solution of 
iPrONa/iPrOD and DMI at 20 C for one hour. NMR studies showed that there was a 40% 
decrease in the integration of the doublet peak for one of the prochiral hydrogen at C2 
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(Appendix B; Figure 3.3), however the doublet peak for another prochiral hydrogen was under 
the peak of hydrogens at C8 (phenyl CH2 side chain) and PMB methyl group, therefore the 
deuterium enrichment cannot be measured with certainty. The isolated yield for compound 
3.10 was 70%. In order to increase the extent of deuterium at C2 the reaction was carried out 
for 1.5 hours and 2 hours as shown in entry 2 and entry 3 respectively. NMR studies for the 
second and third trial indicated the presence of 45% and 50% of deuterium at C2 respectively 
(Appendix B; Figure 3.4 and Figure 3.5). However, when the above mentioned reaction was 
done for prolonged time (longer than 2 hours) cleavage of the -lactam ring became a problem. 
Since the amount of H/D exchange on C2 (50%) after allowable reaction time is not sufficient 
an alternative approach was required. 
 
3.1.3   H/D exchange at C2 position of cephalosporin core using DMSO/Methanol 
 A further search of the literature revealed that Richter et al.61 performed H/D exchange 
at C2 of a cephalosporin sulfoxide derivative using a mixture of DMSO-d6 and methanol-d4 as 
mentioned in Chapter 2. In the present thesis, the experimental conditions mentioned by 
Richter et al., were adopted to perform the H/D exchange on the compound of our interest. 
Therefore, compound 3.16 was prepared from 7-aminocephalosporanic acid 3.11 by first the 
phenyl acetylation on its amino side chain by Schotten-Baumann conditions, using 
phenylacetyl chloride and sodium carbonate as base to give 3.12.67 A suspension of 3.12 in 
ethyl acetate was esterified by stirring with a solution of diphenyldiazomethane 3.14 (prepared 
by reaction of benzophenone hydrazone 3.13 and yellow mercuric oxide) in ethyl acetate 
overnight to give 3.15. This compound was further oxidized to its sulfoxide 3.16 using m-
CPBA.65 NMR studies of compound 3.16 confirmed absence of any sulfone adduct. H/D 
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exchange was performed on the sulfoxide 3.16 using DMSO as a solvent and also very weak 
base and methanol as source of deuterium (Scheme 3.09).  
 
Scheme 3.9: The H/D exchange on C2 of 3.16 using DMSO/methanol under various 
conditions. 
 Although the precise mechanism involved in this H/D exchange is not known with 
certainty, it is worth discussing some possibilities in this regard. DMSO is not normally 
employed as a base. Raman spectroscopic69 and X-ray crystallographic studies reveals that 
DMSO undergoes predominates on the oxygen atom rather than on sulfur. 
 
  DMSO salts are formed with very strong (super) acids.69 The pKa for the conjugate 
acid of DMSO has been estimated to be -1.04.69 The pKa’s for the conjugate acid of alcohols 
(ROH2+) are reported to be approximate -2.5 as compared to -1.74 for hydronium ion.70 So it is 
reasonable to suggest that DMSO is the strongest base in the reaction mixture and may affect 
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the deprotonation of the C2 hydrogens in the cephalosporin sulfoxide. Scheme 3.9 illustrates a 
proposed mechanism for the H/D exchange using DMSO and methanol. 
 
Scheme 3.9: Proposed mechanism for H/D exchange on C2 of compound 3.16 using DMSO 
and methanol. 
  Various changes were undertaken in the experimental conditions during the course of 
H/D exchange (Table 3.3) to optimize the reaction conditions and increase the percentage of 
deuterium incorporation at C2 of compound 3.17. Although Richter and co-workers did not 
mention the quantities of reactants being used for H/D exchange at C2, for the first attempt in 
this study, 10 eq of CD3OD was used.   
 Richter and co-workers reported 70% deuterium incorporation at C2 by 1H NMR. 
Whereas, from the first entry in Table 3.3, here compound 3.17 was obtained in DMSO-d6 
solution and its 1H NMR suggested the incorporation of 75% deuterium at one of the prochiral 
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hydrogens C2 (Appendix B; Figure 3.6). The doublet peak for the second prochiral hydrogen at 
C2 showed interference with the multiplet peak of hydrogens at C8, therefore the deuterium 
enrichment cannot be measured with certainty. Since methanol-d4 acts only as a source of 
deuterium in the reaction in entry 2 it was replaced by MeOD as deuterium source. After the 
reaction completion, NMR studies showed no difference in the amount of deuteration at C2 of 
3.17, compared to the entry 1; where the H/D exchange was done using methanol-d4 (Appendix 
B; Figure 3.7). 
Table 3.3: Modification in experimental conditions for the H/D exchange using 
DMSO/Methanol 
Exp.  
No. 
Reaction conditions Time (h) (%D) by 1H 
NMR 
% 
Yield
1. 3.16: DMSO-d6; CD3OD (10 eq); changed* 
CD3OD every 90 min  
3 75% D at one 
prochiral H of C2 
-NA-
2. 3.16: DMSO-d6; MeOD (10 eq); changed 
CH3OD every 90 min  
3 75% D at one 
prochiral H of C2 
-NA-
3. 3.16: DMSO-d6; MeOD (100 eq); changed 
CH3OD at 24 h and 43 h  
66 87.4% D in both 
prochiral Hs of C2
-NA-
4.  3.16: DMSO-d6; MeOD (100 eq); changed 
CH3OD every 2 h from t = 0 h to t = 8 h  
24 90.2% D in both 
prochiral Hs at C2 
99% 
  
                                                     
 
* Procedure for the change of solvent: After the reaction time of 90 minutes, methanol present in the 
reaction flask was evaporated under high vacuum and then, fresh methanol was introduced to the flask 
and reaction was continued for the above mentioned time duration. For details refer to Section 5.2 in 
Chapter 5 (Experimental Procedure) 
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 Since MeOD is cheaper, it was used in the following reactions as deuterium source 
instead of methanol-d4. To increase the amount of deuteration at C2, the amount of MeOD was 
increased from 10 equivalents to 100 equivalents and the reaction time was increased from 3 
hours to 24 hours. It was believed that increasing the amount of MeOD or increasing the time 
of reaction would facilitate the H/D exchange. After 24 hours, NMR spectroscopy studies 
confirmed 92% of the hydrogen atoms were exchanged by deuterium at C2. The solvent 
(MeOD) was changed and new solvent was introduced to the reaction and it was continued for 
another 19 hours. After 43 hours NMR studies indicated deuterium incorporation of 94% at 
C2. The MeOD was changed and reaction was continued to 66 hours. NMR studies confirmed 
that 94% of one prochiral hydrogen was exchanged by deuterium at C2 of compound 3.17 and 
93% of the second prochiral hydrogen was exchanged (Appendix B; Figure 3.8). Therefore, the 
deuterium enrichment at C2 was found to be (0.94 x 0.93) 87.4%.  From the above results, it 
was evident that the amount of the solvent (MeOD) as well as the frequency of its change was 
very important in increasing the incorporation of deuterium at C2. Time was the third factor of 
modification in this reaction. Thus, it was confirmed that to achieve acceptable results most 
efficiently, the reaction should be done for 24 hours and the solvent (MeOD) should be 
changed frequently. Therefore, in entry 4 the amount of MeOD was kept at 100 equivalents but 
MeOD was changed every 2 hours from t = 0 to t = 8 hours. The reaction was carried out for 
24 hours and NMR spectroscopy studies showed H/D exchange of 97% was achieved on one 
of the prochiral hydrogen at C2 of compound 3.17 and 93% of the second prochiral hydrogen 
was exchanged (Appendix B; Figure 3.9). Therefore, the deuterium enrichment at C2 was 
found to be (0.97 x 0.93) 90.2%.  
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 During the NMR studies of compound 3.16, it was observed that each of the signals for 
the hydrogens at C2 appears as a doublet (Appendix B; Figure 3.11 [A]). Among them, one of 
the doublets for one of the hydrogens at C2 was superimposed with the peak for the methylene 
hydrogens at Ph-CH2 whereas; the doublet peak for the second hydrogen at C2 was isolated at 
down-field position. After the H/D exchange on C2 using DMSO/methanol, it was essential to 
determine that the doublet peak which disappears from the 1H NMR of compound 3.17 
(Appendix B; Figure 3.9), was in fact, for the hydrogens at C2 and not for Ph-CH2. A detail 2D 
NMR for compound 3.15 (Appendix B; Figure 3.10) and 3.16 (Appendix B; Figure 3.11), was 
carried out. Peaks for all the hydrogen and carbon atoms were assigned using COSY, HMQC 
and HMBC experiments. NMR studies of compound 3.15 (Appendix B; Figure 3.10), shows 
that the peak for hydrogen at C2 and Ph-CH2 are superimposed. Therefore it was difficult to 
assign them. However, HMBC study for compound 3.16 confirmed that, the peak which 
diminishes in the 1H NMR of compound 3.17 (Appendix B; Figure 3.9), is for the hydrogens at 
C2. Thus, for compound 3.16 the peak at 3.96 ppm was for hydrogen at C2 (Appendix B; 
Figure 3.11) and not for the hydrogens on the phenylacetyl side chain. After the H/D exchange 
it was this peak at 3.96 ppm which diminishes in compound 3.17 (Appendix B; Figure 3.9). 
NMR studies of compound 3.17 confirmed the presence of 90.2% deuterium enrichment at C2. 
Hence, objective 1 in the present thesis was successfully accomplished with good yield and 
higher percent of deuterium incorporation at the C2 of the cephalosporin compound, compared 
to the previous two methods. 
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3.2  Objective 2: Deuteration at C3ʹ of Cephalosporin Core 
 The second objective for the present study was to synthesize a C3ʹ monodeuterated 
cephalosporin compound. With a method for the deuteration of C2 in hand, the next attention 
was to perform deuteration of C3ʹ hydrogens. Initially, it was proposed that the hydrogens at 
C2 and C3ʹ might undergo a base-catalysis exchange in one pot. However, in all the different 
approaches to perform H/D exchange at C2, there was no exchange observed for C3ʹ 
hydrogens. Therefore, another approach to incorporate deuterium at C3’ was planned. It was 
thought that a functional group interconversion reaction might be carried out at C3ʹ. The 
oxidation of the C3ʹ hydroxyl cephalosporin 3.1 can give the corresponding C3ʹ aldehyde. This 
might then be reduced to an alcohol using a deuterated reducing agent. Thus, to start the first 
trial of the objective 2, compound 3.1 (obtained from Dr. Ahmad Ghavami, in this laboratory) 
was oxidized to the C3ʹ aldehyde 3.18 following a known procedure71 by using 
[bis(acetoxy)iodo]benzene (BAIB) and a catalytic amount of 2,2,6,6-
tetramethylpiperidinyloxyl (TEMPO) in 77% yield. Then, a solution of compound 3.18 was 
stirred with sodium borodeuteride (NaBD4) at room temperature for 1 hour in methanol.  
 
Scheme 3.11: The functional group inter-conversion reaction on C3ʹ hydroxyl cephalosporin. 
 After the workup, the 1H NMR suggested that the reaction failed and the NMR was clearly 
not that of the single reduction product. It was assumed that the product was either lactonized 
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at C3ʹ to give 3.19 or the -lactam ring was hydrolyzed or both (Scheme 3.11). The reason for 
the failure for the reduction of compound 3.18 to give 3.19 was unknown. However, there were 
few possibilities for its failure which included: the possibility that sample of sodium 
borodeuteride was decomposed or that the -lactam ring was cleaved by the methoxide ion 
formed from the reaction of methanol with sodium borodeuteride at higher temperature. The 
same reaction as mentioned in Scheme 3.10 was performed on compound 3.20 (obtained from 
Dr. Ahmad Ghavami, in this research group) since, the amount of compound 3.1 was not 
sufficient to go ahead with the next trials. Also, the experimental conditions used to cleave this 
phenylacetyl side chain were previously performed in this laboratory. Compound 3.20 was 
oxidized to the C3ʹ aldehyde derivative 3.21 using BAIB and a catalytic amount of TEMPO. In 
the second trial, compound 3.21 was reduced using sodium borohydride (NaBH4) instead of 
sodium borodeuteride (NaBD4). The idea was to verify if, the reaction can be performed on 
cephalosporin compounds. The temperature was one of the assumed reasons for the failure of 
first trial. Therefore, in the second trial the reaction was done at 0 C. Reduction reactions 
using sodium borohydride are normally carried out in alcohol solvents; in which the rate of 
reaction is directly related to the structure of the alcohol (methyl > 1 > 2 > 3).72  A solution 
of compound 3.21 was stirred with NaBH4 for an hour in ethanol at 0 C to give 3.20 after 
acidic workup (Scheme 3.12).   
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Scheme 3.12: Reduction of C3ʹ aldehyde using sodium borohydride.  
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 After the second trial of reduction using sodium borohydride, it appeared that the 
failure of the first trial might have resulted from a sodium borodeuteride sample that had 
decomposed. In order to verify the purity of the NaBD4, a solution of 3.22 (benzaldehyde) was 
reduced using NaBH4 and NaBD4 in ethanol at 0 C to give 3.23 and 3.24, respectively 
(Scheme 3.13) 
 
Scheme 3.13: Reduction of benzaldehyde to 3.23 and 3.24. 
 NMR studies confirmed the integrity of the NaBD4 sample after the successful 
reduction of 3.22 to 3.23 (Appendix B; Figure 3.12) and 3.24 (Appendix B; Figure 3.13). 
Compound 3.20 was synthesized from 7-ACA (3.11). The solution of 3.11 was hydrolyzed at 
C3ʹ using sodium hydroxide solution to give compound 3.25. Using a known procedure,67 this 
was further stirred with BSA (bis[trimethylsilyl]acetamide) to protect the free hydroxyl and 
carboxylic acid and then phenyl acetylated at the C7 amino side chain to give compound 3.26. 
The suspension of 3.26 was stirred with a solution of diphenyldiazomethane 3.14 (prepared by 
reaction of benzophenone hydrazone 3.13 and yellow mercuric oxide) in ethyl acetate 
overnight to give 3.20 in 75% yield (Scheme 3.14). 
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Scheme 3.14: Successful attempt of deuteration at C3ʹ of cephalosporin analogues.  
 Further, 3.20 was oxidized to the C3ʹ aldehyde derivative 3.21 using BAIB and a 
catalytic amount of TEMPO in a mixture of dichloromethane (DCM) and tetrahydrofuran 
(THF) in 90% yield. After the first two reduction attempts, it was known that the sample of 
NaBD4 was of good quality and the reaction should be carried out at lower temperature to 
prevent reaction with the -lactam ring. Since the reaction was carried out at low temperature, 
it was thought to use methanol as solvent because the rate of reaction with methanol is faster 
compared to ethanol.72 Therefore, the reduction of 3.21 was done in methanol using NaBD4 at 
30 C. The reaction was carried out for an hour to give 3.30 after acidic workup. A literature 
review suggest that, compound 3.20 in presence of acidic/basic condition tends to form the C3ʹ 
lactone.67 It was thought that due to excess addition of an acid to quench the reaction the C3ʹ 
hydroxyl anion would attack the C4 carboxylate ester and would form a lactone with cleavage 
of the diphenylmethyl protecting group. In order to avoid any possibility of forming a lactone, 
in the present trial, saturated ammonium chloride solution (NH4Cl) was used to do the acidic 
workup compared to the previous trial where hydrochloric acid was used. Since, saturated 
NH4Cl is mildly acidic and would be less prone to bring about lactone formation. 1H NMR of 
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the monodeuterated cephalosporin 3.27 confirms the presence of one deuterium at the C3ʹ 
position of the core because the integration of C3ʹ hydrogens was decreased by one (Appendix 
B; Figure 3.14 [A]). Interestingly, the difference in the multiplicity of C3ʹ hydrogen was 
observed with the change in the NMR solvent. When DMSO-d6 was used as NMR solvent the 
peak for the C3ʹ hydrogen appears as a singlet with integration of two compared to H7 for the 
non-labelled compound 3.20. However, when the NMR experiment was performed using 
acetone-d6 as solvent, the peak for C3ʹ hydrogen appears as a multiplet. NMR studies for the 
monodeuterated hydroxyl compound 3.27 suggest, when DMSO-d6 was used as NMR solvent 
the peak for C3ʹ hydrogen appears as a singlet with integration of one compared to H7 
(Appendix B; Figure 3.14). However, when the NMR experiment was performed using 
acetone-d6 as solvent, the peak for C3ʹ hydrogen appears as a multiplet. This indicates that the 
reduction gave a mixture in which one of the prochiral hydrogen positions was enriched to a 
greater extent (approximately 4:1) than the other.  
 It then occurred that possibly compound 3.27 might be oxidized to the aldehyde 3.28 
which would preferably eliminate the hydrogen because of a secondary deuterium isotope 
effect and the subsequent reduction using sodium borodeuteride would introduce another 
deuterium at C3ʹ. Thereafter, it was important to check if the re-oxidation of 3.27 to aldehyde 
3.28 would show a significant primary deuterium isotope effect and react to give preferentially 
the deuterated aldehyde. In fact, when compound 3.27 was stirred with BAIB and TEMPO in 
dichloromethane and tetrahydrofuran for 24 hours gave 3.28 in 90% yield (Scheme 3.15). The 
1H NMR suggests presence of 1:1 ratio of H:D for its aldehyde peak (Appendix B; Figure 
3.15).   
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Scheme 3.15: Re-oxidation of C3ʹ deuterated hydroxyl derivative to aldehyde 3.28. 
 
3.3  Objective 3: Synthesis of a Core Trideuterated Cephalosporin Analogue 
 After successful accomplishment of objective 1 and objective 2, in order to synthesize 
the trideuterated compound both the strategies which were used to achieve objective 1 and 2 
were combined and a plan was proposed as shown in scheme 3.16. The research objectives 
accomplished in this thesis were briefly described in this chapter earlier. A proposed approach 
to combine objective 1 and 2 for preparation of core trideuterated cephalosporin compound is 
shown in Scheme 3.16. 7-ACA was chosen as the staring material for the synthesis. Thus, 3.11 
can be acylated with phenylacetyl chloride or 2-thienylacetyl chloride to give compound 3.29 
under Schotten-Baumann conditions. The carboxylic acid functional group of compound 3.29 
can then be protected either as a benzhydryl ester or a PMB ester to give compound 3.30 which 
can then be oxidized to give sulfoxide 3.31. H/D exchange on 3.31 will give 3.32 and its 
subsequent reduction will yield 3.33 as a dideuterated derivative. Cephalosporins esterified at 
the C4 position tend to undergo 2 and 3 isomerization in presence of base. Therefore, to 
avoid the isomerization, compound 3.33 can be deprotected to give free acid 3.34. The acetoxy 
ester functional group of compound 3.34 can be hydrolyzed using sodium hydroxide to give 
3.35. In order to oxidize compound 3.35, it can first be protected at C4 to give 3.36 which can 
then be oxidized to an aldehyde and then be reduced back to a C3ʹ alcohol 3.37 as a core 
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trideuterated cephalosporin compound. Compound 3.37 can be chlorinated at the C3ʹ side 
chain using thionyl chloride and then cleaved at its C7 side chain to give the free amino 
derivative 3.38. The free amino derivative could then be used as a starting material for the 
synthesis of internal standards for a variety of experimental cephalosporin antibiotics. These 
isotopically labelled compounds can then be useful as internal standards to perform 
pharmacokinetic analysis of their unlabeled derivatives using LC/MS methods.  
 
Scheme 3.16: Proposed plan for synthesis of trideuterated core cephalosporin. 
  Scheme 3.17 shows the preparation of trideuterated compound 3.44. As mentioned 
earlier in Scheme 3.9, 7-ACA (3.11) was phenylacetylated to give 3.12 under Schotten-
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Baumann conditions in 95% yield. The phenylacetyl derivative was synthesized because in the 
later stage its C7 hydrolysis was previously performed in the Dmitrienko group with good 
yield. Compound 3.12 was esterified at C4 using a solution of diphenyldiazomethane 3.14 in 
ethyl acetate to give 3.15 in 82% yield. The sulfoxide 3.16 was prepared again by the same 
experimental procedure from 3.15 using m-CPBA in dichloromethane in 87% yield. 
Compound 3.16 was stirred with DMSO and methanol-OD (50 equivalents) for 16 hours, then 
the solvent was evaporated and new methanol-OD was added and the reaction was continued 
for 24 hours to give compound 3.17 in quantitative yield. The 1H NMR of 3.17 reveals that the 
amount or percentage of deuterium incorporation for one of the prochiral hydrogens at C2 was 
found to be 96% and 93% for the second prochiral hydrogen (Appendix B; Figure 3.16). 
Therefore, the deuterium enrichment at C2 was calculated to be (0.96 x 0.93) 89.2%. Thus, 
compound 3.17 was then reduced back to its sulfide 3.39 using phosphorous trichloride in 
dimethylformamide (DMF) at 30 C in 95% yield.  As mentioned earlier in Scheme 3.3, 
cephalosporins esterified at the C4 position tend to undergo 2 and 3 isomerization in 
presence of base. Therefore, to avoid the isomerization, compound 3.39 was deprotected at C4 
position using trifluoroacetic acid and anisole at 0 C to give the free acid 3.40 in 75% yield. 
This free acid 3.40 underwent deacetylation/hydrolysis at its C3ʹ side chain to give the 
compound 3.41 in 35% yield. The reason for the low yield is because, it is known from the 
literature that during the hydrolysis of this acetoxy group at C3ʹ side chain forms lactone as a 
side product under strong acidic and basic conditions.67  The 1H NMR for compound 3.41 
shows no back exchange of deuterium at C2, nor any isomerization to the 2 isomer. The 
successful completion of the hydrolysis reaction was a important step in the present project.  
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 Further, 3.41 was esterified using the same procedure as mentioned earlier to give 
compound 3.42 in 72% yields. Compound 3.42 was then oxidized using TEMPO and BAIB in 
a mixture of dichloromethane and tetrahydrofuran to give dideuterated aldehyde 3.43 in 97% 
yield. The aldehyde 3.43 was then reduced with NaBD4 in methanol at 30 C. Saturated 
solution of NH4Cl was used to quench the reagents during the workup which afforded core 
trideuterated cephalosporin compound 3.44 in 50% yield (scheme 3.17).   
 
Scheme 3.17: The synthesis of core trideuterated cephalosporin. 
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 NMR studies of compound 3.44 indicated that, there was a difference in the multiplicity 
of C3ʹ hydrogen peaks with the change in the NMR solvent as mentioned earlier in Scheme 
3.14. When DMSO-d6 was used as the NMR solvent, the peak for C3ʹ hydrogen appears as a 
singlet with integration of one compared to H7 (Appendix B; Figure 3.17 [A]). However, when 
the NMR was done using acetone-d6 as solvent, the peak for C3ʹ hydrogen appears as a 
multiplet. The relative integration indicates that the reduction gave a mixture in which one of 
the prochiral hydrogen positions is been enriched to a greater extent (approximately 4:1) than 
the other (Appendix B; Figure 3.17 [B]). From the NMR studies the deuterium enrichment 
cannot be measured with certainty for compound 3.44. Since the signal for hydrogens at C2 is 
overlapped with the peak of hydrogens at C8 (phenyl-CH2 side chain). The deuterium 
enrichment for C3ʹ from its NMR integration of the peak was found to be 98%. Thus, with the 
synthesis of compound 3.44 the attempt to synthesize the core trideuterated derivate was 
successfully achieved. 
 
3.4  Modified Route for the Synthesis of the Core Trideuterated Cephalosporin 
Analogue 
 Scheme 3.17 represents the synthesis of trideuterated cephalosporin 3.44 in 11 steps. 
After the first successful attempt for the synthesis of trideuterated analogue, the next challenge 
was to reduce the synthesis steps to make it more efficient and additionally, increase the 
overall yield for the synthesis of core trideuterated compound. It was proposed that by avoiding 
the C4 esterification step and deprotection of the benzhydryl group, both the above mentioned 
challenges might be answered. Scheme 3.18 shows the modified route of synthesis. Herein, the 
synthesis started from 3.11 (7-ACA) as mentioned earlier in other schemes. This compound 
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was phenylacetylated on the C7 amino side chain to give 3.12 in excellent yields. Further, 3.12 
was directly oxidized to the sulfoxide 3.45 using m-CPBA in 97% yield.73 Compound 3.45 
underwent H/D exchange at C2 of using DMSO and methanol-OD (20 equivalents). An effort 
was made to reduce the duration of the H/D exchange reaction. Therefore, methanol-OD was 
changed every two hours and the reaction was done for only 6 hours. Compound 3.46 was 
obtained in quantitative yields and 1H NMR spectroscopy of 3.46 reveals the presence of 95% 
deuterium incorporation at one of the prochiral hydrogens of C2 (Appendix B; Figure 3.18). 
The dideuterated compound 3.46 was reduced back to its sulfide form 3.40 using phosphorous 
trichloride at 30 C in DMF. The mass spectrum for 3.40 shows the presence of the ratio of 
the dideuterated compound to the monodeuterated as 10:1 (Appendix B; Figure 3.19). Thus 
this infers that after the H/D exchange on compound 3.45 approximately 91% of both the 
prochiral hydrogens were exchanged by deuterium at C2 of core cephalosporin. Compound 
3.40 was hydrolyzed at C3ʹ using sodium hydroxide at 20 C to give 3.41 in 50% yield. 
Synthesis of 3.42 was done by esterification of 3.41 at C4 using a solution of 
diphenyldiazomethane 3.14 in ethyl acetate. The functional group interconversion reactions 
were performed on 3.42 in which oxidation to aldehyde afforded compound 3.43 in 98% yield 
and its reduction resulted in core trideuterated hydroxyl derivative 3.44 in 62% yield. 
According to the NMR studies of compound 3.44 in benzene-d6 and a drop of DMSO-d6 the 
deuterium incorporation in the core cephalosporin compound was determined to be 95% for 
one of the prochiral hydrogen and 94% for the second prochiral hydrogen at C2 (Appendix B; 
Figure 3.20).There was a difference in the multiplicity of the C3ʹ hydrogen with the change in 
the NMR solvent as mentioned earlier in Scheme 3.14. (Appendix B; Figure 3.20 [A and B]). 
1H NMR spectroscopy of compound 3.44 in acetone-d6 suggests 98% of isotopic enrichment at 
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C3ʹ. Also, 13C NMR shows the peak for C3ʹ as a triplet due to the presence of deuterium 
(Appendix B; Figure 3.20 [C]). The mass spectrum for compound 3.44 shows a presence of 
trideuterated: dideuterated in a ratio of 5:1 (Appendix B; Figure 3.20[D]). Thus, the synthesis 
of a core trideuterated compound 3.44 having deuterium enrichment of (0.94 x 0.95 x 0.98) 
87.5% by NMR spectroscopic studies. After performing the calculation from the mass 
spectrometric analysis it was found that the estimated ratio of the trideuterated compound to 
the dideuterated compound was 5 to 1.  
 
Scheme 3.18: Modified route of synthesis for core trideuterated cephalosporin analogue.  
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Chapter 4 
Concluding statements 
4.1  Summary and conclusion 
 The main goal of this thesis was to synthesize a core trideuterated cephalosporin 
compound. The isotope labelled compound can be then used to synthesize internal standards 
for novel cephalosporin derivatives. The proposed sites for deuteration were C2 and C3ʹ of the 
core cephalosporin structure. The synthesis involves hydrogen-deuterium exchange of the C2 
hydrogens of a cephalosporin sulfoxide in a mixture of DMSO and O-deuterated methanol and 
reduction of the C3ʹ aldehyde group by sodium borodeuteride. Later, both the approaches were 
combined on one molecule and a method for synthesis of a triply deuterated cephalosporin core 
structure 3.44 has been devised.  
 
 The exchange process at C2 resulted in a deuterium enrichment of 95% in each of the 
prochiral hydrogen positions as estimated by proton NMR signal integration.  The aldehyde 
reduction led to a mixture with one of the prochiral hydrogen positions being enriched to a 
greater extent (approximately 4:1) than the other.  The deuterium enrichment at C3 was 
approximately 98% as estimated by integration of the NMR signals for the C3ʹ hydrogens.  
This leads to the conclusion that the sample is approximately (0.95 x 0.95 x 0.98) 88.5% 
trideuterated. 
 A preliminary mass spectrometric analysis estimates the ratio of the trideuterated 
cephalosporin to the dideuterated variant as 5 to 1. Since there is precedent for transformation 
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of the unlabeled version of 3.44 into the cephalosporin synthon 3.47, the availability of 3.44 
should allow researchers in this laboratory and elsewhere to prepare internal standards for MS 
analysis of new cephalosporin drug candidates in pharmacokinetic studies. 
 
4.2  Future Work 
 Potential future improvements in the preparation of 3.44 could focus on increasing the 
level of deuterium incorporation by further variation of the methods developed in this study.  
The level of deuterium incorporation at C3ʹ is essentially that of the deuterium source NaBD4 
so that it is not clear how this step might be improved unless a source of more highly enriched 
NaBD4 could be identified.  On the other hand, the deuterium incorporation at C2 is 95% 
whereas the deuterium source methanol-OD (CH3OD) is labeled to the extent of 99%.  Thus, 
efforts might be made to improve this process by extending the reaction times and increasing 
the relative amount and frequency of replacement of the deuterated solvent. 
 Another strategy for deuterium incorporation that might be explored in future involves 
the creation of a tetradeuterated product through C2 hydrogen exchange as done in this work 
combined with a reduction of a C3ʹ carboxylic acid group using trideuteroborane-THF 
complex. 
2 2
3
2 2  
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 The deuterated compound 3.44 should be converted in to the labeled synthon 3.47 to 
establish if any back exchange of hydrogen for deuterium occurs in any of the steps.  Also, the 
synthon 3.47 should be subjected to typical N-acylation, chloride displacements by typical 
nucleophiles and removal of the benzhydryl protecting group to determine if any back-
exchange occurs in such transformations. 
 In future use of such a trideuterated species in LC/MS/MS studies it will be necessary 
to establish the separation and ionization conditions that are ideal for the specific cephalosporin 
derivative under study.  Attention will need to be paid in such studies to any possibility that the 
MS ionization conditions might result in any back exchange of the deuterium by protium from 
the ionization medium that will likely include acid or base.  
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Chapter 5 
Experimental Procedure 
5.1 General Procedures 
 All the experimental reaction were always done in flame and oven-dried glassware 
under nitrogen atmosphere and at room temperature (rt); where not mentioned. All the 
experimental reagents and chemicals were obtained from Sigma Aldrich ®, Alfa Aesar ®, 
Cambridge Isotopes Inc. ® etc. Solvents used in the reaction were either reagent grade and/or 
HPLC grade. The reactions were stirred magnetically and monitored by TLC using Merck pre-
coated silica plates (silica gel 60 F254 on aluminium sheet). Compounds were purified by flash 
chromatography using SiliCycle silica gel (60 Å). The yields reported are for the isolated 
compounds. 1H NMR and 13C NMR spectra were recorded on Bruker ® 300 MHz and 500 
MHz spectrometer using chloroform-d, DMSO-d6, acetone-d6, D2O and benzene-d6. All the 
chemical shifts are reported in parts per million (ppm) relative to tetramethylsilane (TMS). For 
1H NMR spectra, the chemical shift was calibrated relative to the signal of the proton for the 
isotopomer with one less deuterium than the perdeuterated solvent (Chloroform: H 7.26; 
DMSO-d6: H 2.50; Acetone-d6: H 2.05; Benzene-d6: H 7.16; HDO: H 4.79) as reported by 
Gottilieb et al.74 For 13C NMR spectra, the chemical shift scale was calibrated relative to that of 
the 13C signal of the perdeuterated solvent (Chloroform: C 77.16; DMSO-d6: C 39.52) as 
reported by Gottilieb et al.74 Peak multiplicities were represented by abbreviations such as: s, 
singlet; d, doublet; t, triplet; q, quartet; qAB, AB quartet; dd, doublet of doublets; m, multiplet; 
gem, geminal. The coupling constants have uncertainties of ±0.5 Hz. The protons and carbons 
were assigned depending on their respective data from 2-dimensional NMR experiments 
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including COSY, HMQC and HMBC. Low Resolution Mass Spectra (LRMS) and High 
Resolution Mass Spectra (HRMS) analysis were obtained via electrospray ionization (ESI), 
were measured by Thermo Scientific Q ExactiveTM plus Hybrid Quadrupole-OrbitrapTM Mass 
Spectrometry Facility in the Department of Chemistry, University of Waterloo.  
 
5.2 Synthetic Procedures 
 
Compound 3.1 was obtained from Dr. Ahmad Ghavami. 1H NMR (300 MHz, CDCl3): 3.53 
(s, 2H, SCH2), 3.84 (s, 2H, thiophene-CH2), 3.93 (d, Jgem = 13.0 Hz, 1H, CH2OH), 4.39 (d, Jgem 
= 13.0 Hz, 1H, CH2OH), 4.93 (d, J6,7 = 4.8 Hz, 1H, H6), 5.88 (dd, J6,7 = 4.8 Hz, J7,NH = 9.1 Hz, 
1H, H7), 6.51 (d, J7,NH = 9.1 Hz, 1H, NH), 6.89 (s, 1H, CHPh2), 6.98 (m, 2H, thiophene), 7.35 
(m, 11H, Ar; thiophene). 13C NMR (75.5 MHz, CDCl3):27.71, 37.21, 57.16, 59.15, 62.16, 
80.15, 124.96, 126.20, 127.18, 127.60, 127.68, 128.02, 128.38, 128.60, 128.79, 133.55, 134.80, 
139.05, 139.29, 161.83, 165.14, 170.24. 
2 2 2 2  
To a stirring solution of 3.1 (260 mg, 0.50 mmol) in dichloromethane (2 mL) was added a 
solution of DMAP (6 mg, 0.05 mmol) and pyridine (81 L, 1.00 mmol) in dichloromethane (2 
mL) at 0 C, 4-chlorobenzoyl chloride (77 µL, 0.50 mmol) was added slowly and was allowed 
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to react overnight. The solvent was evaporated in vacuo. The residue was dissolved in EtOAc 
(20 mL), washed with H2O (3  20 mL) and brine (30 mL). The organic layer was dried over 
anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified 
by flash chromatography (EtOAc:hexanes; 1:3) to give 3.2 (207 mg, 0.31 mmol, 73%). 1H 
NMR (300 MHz, CDCl3): 3.42 (d, Jgem = 18.5 Hz, 1H, SCH2), 3.60 (d, Jgem = 18.5 Hz, 1H, 
SCH2), 3.88 (s, 2H, thiophene-CH2), 5.01 (m, 2H, CH2OCO; H6), 5.29 (d, J = 13.6 Hz, 1H, 
CH2OCO), 5.89 (dd, J6,7 = 4.9 Hz, J7,NH = 9.0 Hz, 1H, H7), 6.36 (d, J7,NH = 9.0 Hz, 1H, NH), 
6.99 (m, 3H, CHPh2; thiophene), 7.36 (m, 12H, Ar), 7.89 (d, J = 8.5 Hz, 2H, Ar), 8.03 (d, J = 
8.5 Hz, 1H, thiophene). 13C NMR (75.5 MHz, CDCl3):26.70, 37.24, 57.42, 59.30, 63.78, 
80.02, 126.10, 126.30, 126.55, 127.17, 127.76, 127.82, 128.13, 128.28, 128.42, 128.62, 128.70, 
129.02, 131.22, 131.70, 134.72, 139.03, 139.23, 140.10, 160.77, 164.80, 165.35, 170.17. 
 
To a solution of 3.2 (89 mg, 0.13 mmol) in dichloromethane (10 mL) at 0 C was added m-
CPBA (35 mg, 0.20 mmol) at once and the reaction was stirred for 3 hours. The solvent was 
evaporated in vacuo and the residue was dissolved in EtOAc (20 mL), washed with H2O (20 
mL), sat. NaHCO3 (20 mL) and brine (30 mL). The organic layer was dried over anhydrous 
Na2SO4 and concentrated under reduced pressure to give 3.3 (51 mg, 0.07 mmol, 56%). 1H 
NMR (300 MHz, CDCl3): 3.20 (d, Jgem = 18.2 Hz, 1H, SCH2), 3.84 (m, 3H, SCH2; 
thiophene-CH2), 4.45 (d, J6,7 = 4.2 Hz, 1H, H6), 4.93 (d, Jgem = 13.90 Hz, 1H, CH2OCO), 5.51 
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(d, Jgem = 13.90 Hz, 1H, CH2OCO), 6.10 (dd, J6,7 = 4.6 Hz, J7,NH = 9.5 Hz, 1H, H7), 6.96 (m, 
4H, NH; thiophene; CHPh2), 7.37 (m, 13H, Ar; thiophene), 7.88 (d, J = 8.7 Hz, 2H, Ar). 
 
 
A solution of 3.3 (50 mg, 0.07 mmol) in benzene (9 mL) and D2O (10 mL) was allowed to 
reflux (80 C) for 136 hours. The solvent was evaporated in vacuo and the residue was dried 
under vacuum pump to give 3.4 (48 mg, 0.07 mmol, 95%) as a yellow solid. 1H NMR (300 
MHz, CDCl3): 3.15 (s, 0.22H and 0.78D, SCX2, where X = H/D), 3.85 (m, 2.47H, SCX2, 
where X = H/D; thiophene-CH2), 4.47 (d, J6,7 = 4.2 Hz, 1H, H6), 4.94 (d, Jgem = 14.0 Hz, 1H, 
CH2OCO), 5.5 (d, Jgem = 14.0 Hz, 1H, CH2OCO), 6.08 (d, J6,7 = 4.2 Hz, 1H, H7), 7.00  (m, 3H; 
thiophene; CHPh2), 7.36 (m, 13H, Ar; thiophene), 7.87 (d, J = 8.1 Hz, 2H, Ar). 13C NMR (75.5 
MHz, CDCl3):37.18, 53.56, 59.20, 63.97, 66.93, 80.57, 120.93, 125.94, 127.17, 127.48, 
127.70, 127.87, 128.34, 128.42, 128.65, 128.75, 129.07, 131.21, 134.76, 138.95, 139.04, 
140.22, 159.88, 164.23, 165.31, 170.58. 
 
Compound 3.5 was commercially available. 1H NMR (300 MHz, DMSO-d6): 3.52 (m, 3H, 
SCH2; Ph-CH2), 3.73 (m, 4H, SCH2; OCH3), 4.49 (m, 2H, CH2Cl), 5.20 (m, 3H, H6; PMB-
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CH2), 5.73 (dd, J6,7 = 4.9 Hz, J7,NH = 8.7 Hz, 1H, H7), 6.93 (d, J = 8.6 Hz, 2H, Ar), 7.28 (m, 
7H, Ar), 9.11 (d, J7,NH = 8.7 Hz, 1H, NH). 
 
To the suspension of 3.5 (3000 mg, 6.16 mmol) in acetone (30 mL) at 0 C was added NaI 
(1015 mg, 6.77 mmol) at once and the reaction mixture was stirred for 2 hours. Thiobenzoic 
acid (0.86 mL, 1029 mg, 7.39 mmol) was added to above reaction flask followed by Na2CO3 
(979 mg, 9.24 mmol) at once and stirred overnight. The solvent was concentrated under 
reduced pressure and crude product was purified by flash chromatography (EtOAc:hexanes; 
1:3) gave 3.6 (2500 mg, 4.25 mmol, 70%) as a white solid. 1H NMR (300 MHz, CDCl3): 
3.35 (d, Jgem = 18.7 Hz, 1H, SCH2), 3.61 (m, 3H, SCH2; Ph-CH2), 3.74 (s, 3H, OCH3), 3.97 
(d, Jgem = 13.5 Hz, 1H, CH2-SCO-), 4.30 (d, Jgem = 13.5 Hz, 1H, CH2-SCO-), 4.91 (d, J6,7 = 
4.9 Hz, 1H, H6), 5.23 (m, 2H, PMB-CH2), 5.80 (dd, J6,7 = 4.9 Hz, J7,NH = 9.1 Hz, 1H, H7), 5.99 
(d, J7,NH = 9.1 Hz, 1H, NH), 6.88 (d, J = 8.6 Hz, 2H, Ar), 7.32 (m, 7H, Ar), 7.46 (t, J = 7.9 Hz, 
2H, Ar), 7.6 (t, J = 7.8 Hz, 1H, Ar), 7.93 (d, J = 7.3 Hz, 1H, Ar). 13C NMR (75.5 MHz, 
CDCl3):27.82, 30.65, 43.54, 55.41, 57.46, 59.26, 68.15, 66.93, 114.12, 124.96, 126.99, 
127.56, 127.96, 128.67, 128.90, 129.40, 129.61, 130.90, 133.67, 134.01, 136.41, 161.75, 
164.60, 171.17, 191.57. 
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To a solution of 3.6 (588 mg, 1.00 mmol) in dichloromethane (15 mL) at 0 C was added m-
CPBA (292 mg, 1.30 mmol) at once and allowed to react for 3 hours gradually warm up to rt. 
Upon completion the solvent was evaporated in vacuo and the residue was dissolved in EtOAc 
(30 mL), washed with H2O (2  20 mL), sat. NaHCO3 (2  20 mL) and brine (2  30 mL). The 
organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to 
give 3.7 (519 mg, 0.86 mmol, 86%) as a white solid. 1H NMR (300 MHz, CDCl3): 3.30 (d, 
Jgem = 18.5 Hz, 1H, SCH2), 3.61 (m, 2H, Ph-CH2), 3.78 (m, 4H, SCH2; OCH3), 3.94 (d, Jgem = 
13.9 Hz, 1H, CH2-SCO-), 4.40 (dd†, J6,7 = 4.8 Hz, J = 1.5 Hz, 1H, H6), 4.47 (d, Jgem = 13.9 Hz, 
1H, CH2-SCO-), 5.28 (m, 2H, PMB-CH2), 6.03 (dd, J6,7 = 4.8 Hz, J7,NH = 10.1 Hz, 1H, H7), 
6.67 (d, J7,NH = 10.1 Hz, 1H, NH), 6.89 (d, J = 8.7 Hz, 2H, Ar), 7.32 (m, 7H, Ar), 7.46 (t, J = 
7.7 Hz, 2H, Ar), 7.6 (t, J = 7.3 Hz, 1H, Ar), 7.91 (d, J = 7.4 Hz, 1H, Ar). 13C NMR (75.5 MHz, 
CDCl3):30.81, 43.64, 47.40, 55.43, 59.33, 66.98, 68.45, 114.17, 122.56, 125.07, 127.60, 
127.77, 128.93, 129.21, 129.49, 130.98, 133.73, 134.16, 160.13,164.08, 171.30, 203.58.  
 
A solution of 3.7 (50 mg, 0.08 mmol) in benzene (10 mL) and D2O (5 mL) was allowed to 
reflux (80 C) for 154 hours. The solvent was evaporated in vacuo and the residue was dried 
under vacuum pump to give 3.8 (49 mg, 0.08 mmol, 99%). 1H NMR (300 MHz, CDCl3): 
3.31 (d, J = 14.0 Hz, 0.72H and 0.28D, SCX2, where X= H/D), 3.62 (m, 2H, Ph-CH2), 3.81 
                                                     
 
† H6 may be showing a long range W-effect coupling with H2. 
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(m, 4.11H, SCX2, where X= H/D; OCH3), 3.94 (d, Jgem = 13.8 Hz, 1H, CH2-SCO-), 4.40 (dd‡, 
J6,7 = 4.8 Hz, J = 2.0 Hz, 1H, H6), 4.47 (d, Jgem = 13.8 Hz, 1H, CH2-SCO-), 5.28 (m, 2H, 
PMB-CH2), 6.03 (dd, J6,7 = 4.8 Hz, J7,NH = 10.3 Hz, 1H, H7), 6.66 (d, J7,NH = 10.3 Hz, 0.6H, 
NH), 6.89 (d, J = 8.7 Hz, 2H, Ar), 7.32 (m, 7H, Ar), 7.46 (t, J = 8.0 Hz, 2H, Ar), 7.6 (t, J = 7.4 
Hz, 1H, Ar), 7.91 (d, J = 7.2 Hz, 1H, Ar). 
 
To a solution of 3.5 (487 mg, 1.00 mmol) in dichloromethane (10 mL) at 0 C was added m-
CPBA (224 mg, 1.30 mmol) at once and allowed to stir for 3 hours, gradually warm  up to rt. 
Upon completion the solvent was evaporated in vacuo and the residue was dissolved in EtOAc 
(30 mL), washed with H2O (2  20 mL), sat. NaHCO3 (2  20 mL) and brine (2  30 mL). The 
organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to 
give 3.9 (490 mg, 0.97 mmol, 97%; 80% sulfoxide and 20% sulfone) as a white solid. 1H NMR 
(300 MHz, DMSO-d6): 3.66 (m, 6H, SCH2; Ph-CH2; OCH3), 3.93 (d, Jgem = 17.7 Hz, 1H, 
SCH2), 3.50 (d, Jgem = 11.0 Hz, 1H, CH2Cl), 4.67 (d, Jgem = 11.0 Hz, 1H, CH2Cl), 4.92 (d, J6,7 
= 4.9 Hz, 1H, H6), 5.28 (m, 2H, PMB-CH2), 6.03 (dd, J6,7 = 4.9 Hz, J7,NH = 8.0 Hz, 1H, H7), 
6.94 (d, J = 8.4 Hz, 2H, Ar), 7.32 (m, 7H, Ar), 8.46 (d, J7,NH = 8.0 Hz, 1H, NH).  
                                                     
 
‡ H6 may be showing a long range W-effect coupling with H2. 
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To a solution of iPrONa/iPrOD [prepared by reaction of NaH (32 mg, 0.79 mmol) and iPrOD 
(1.8 mL)] was added 3.9 (100 mg, 0.20 mmol) in iPrOD (3 mL) and DMI (0.8 mL) at 20 C. 
The reaction was stirred for 1 hour at the same temperature. Upon completion the reaction 
mixture was poured into sat. NH4Cl solution (20 mL) and extracted with CH2Cl2 (3  30 mL). 
The combined organic phase was washed with brine (20 mL), dried over anhydrous Na2SO4 
and concentrated under reduced pressure to give 3.10 (71 mg, 0.14 mmol, 70%, 80% sulfoxide 
and 20% sulfone) as a white solid. 1H NMR (300 MHz, DMSO-d6): 3.66 (m, 6.57H, SCX2, 
where X= H/D; Ph-CH2; OCH3), 3.89 (d, J = 17.6 Hz, 0.6H and 0.4D, SCX2, where X= H/D), 
4.50 (d, Jgem = 11.7 Hz, 1H, CH2Cl), 4.67 (d, Jgem = 11.7 Hz, 1H, CH2Cl), 4.92 (d, J6,7 = 4.8 
Hz, 1H, H6), 5.25 (m, 2H, PMB-CH2), 5.85 (dd, J6,7 = 4.8 Hz, J7,NH = 8.3 Hz, 1H, H7), 6.94 (d, 
J = 8.7 Hz, 2H, Ar), 7.29 (m, 7H, Ar), 8.4 (d, J7,NH = 8.3 Hz, 0.5H, NH).  
2
i
i
i
2
 
To a solution of iPrONa/iPrOD [prepared by reaction of NaH (32 mg, 0.79 mmol) and iPrOD 
(1.8 mL)] was added 3.9 (100 mg, 0.20 mmol) in iPrOD (3 mL) and DMI (0.8 mL) at 20 C. 
The reaction stirred done for 1.5 hour at the same temperature. Upon completion the reaction 
mixture was poured into sat. NH4Cl solution (20 mL) and extracted with CH2Cl2 (3  30 mL). 
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The combined organic phase was washed with brine (20 mL), dried over anhydrous Na2SO4 
and concentrated under reduced pressure to give 3.10 (60 mg, 0.11 mmol, 60%, 80% sulfoxide 
and 20% sulfone) as a white solid. 1H NMR (300 MHz, DMSO-d6): 3.76 (m, 6.3H, SCX2, 
where X= H/D; Ph-CH2; OCH3), 3.92 (d, J = 17.8 Hz, 0.55H and 0.45D, SCX2 where X= H/D), 
4.50 (d, Jgem = 11.4 Hz, 1H, CH2Cl), 4.67 (d, Jgem = 11.4 Hz, 1H, CH2Cl), 4.92 (d, J6,7 = 4.9 
Hz, 1H, H6), 5.25 (m, 2H, PMB-CH2), 5.85 (dd, J6,7 = 4.9 Hz, J7,NH = 8.3 Hz, 1H, H7), 6.94 (d, 
J = 8.6 Hz, 2H, Ar), 7.34 (m, 7H, Ar), 8.4 (d, J7,NH = 8.3 Hz, 0.4H, NH).  
 
To a solution of iPrONa/iPrOD [prepared by reaction of NaH (32 mg, 0.79 mmol) and iPrOD 
(1.8 mL)] was added 3.9 (100 mg, 0.20 mmol) in iPrOD (3 mL) and DMI (0.8 mL) at 20 C. 
The reaction was stirred for 2 hour at the same temperature. Upon completion the reaction 
mixture was poured into sat. NH4Cl solution (20 mL) and extracted with CH2Cl2 (3  30 mL). 
The combined organic phase was washed with brine (20 mL), dried over anhydrous Na2SO4 
and concentrated under reduced pressure to give 3.10 (60 mg, 0.11 mmol, 60%, 80% sulfoxide 
and 20% sulfone) as white solid. 1H NMR (300 MHz, DMSO-d6): 3.65 (m, 6.5H, SCX2, 
where X= H/D; Ph-CH2; OCH3), 3.92 (d, J = 17.8 Hz, 0.5H and 0.5D, SCX2, where X= H/D), 
4.50 (d, Jgem = 11.4 Hz, 1H, CH2Cl), 4.67 (d, Jgem = 11.4 Hz, 1H, CH2Cl), 4.93 (d, J6,7 = 4.6 
Hz, 1H, H6), 5.25 (m, 2H, PMB-CH2), 5.85 (dd, J6,7 = 4.9 Hz, J7,NH = 8.2 Hz, 1H, H7), 6.94 (d, 
J = 8.6 Hz, 2H, Ar), 7.29 (m, 7H, Ar), 8.4 (d, J7,NH = 8.2 Hz, 0.3H, NH).  
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Compound 3.11 was commercially available, aka 7-aminocephalosporanic acid. 1H NMR (300 
MHz, D2O): 1.64 (s, 3H, COCH3), 3.20 (d, Jgem = 18.2 Hz, 1H, SCH2), 3.34 (d, Jgem = 18.2 
Hz, 1H, SCH2), 4.47 (m, 2H, CH2-OAc), 4.72 (d, J6,7 = 5.0 Hz, 1H, H6), 4.85 (d, J6,7 = 5.0 Hz, 
1H, H7). 
 
To a solution of Na2CO3 (2150 mg, 20.19 mmol) in water (30 mL) and acetone (25 mL) cooled 
down to 5 C was added 3.11 (5000 mg, 18.36 mmol) and stirred for 10 minutes. A solution 
of phenylacetyl chloride (2.7 mL, 20.19 mmol) in acetone (6.2 mL) was added to the above 
reaction mixture using syringe pump over the period of 3 hours at 5 C to 0 C. Water (25 
mL) was added to above reaction flask and was allowed to stir at the same temperature for 
another 2 hours. After reaction completion EtOAc (30 mL) was added and the reaction was 
acidified to pH of 3.0 using 10% HCl solution (10 mL). The organic layer was separated and 
aqueous layer was extracted with EtOAc (3 mL). The organic phase was combined and 
washed with brine (30 mL), dried over anhydrous Na2SO4 and concentrated under reduced 
pressure. The residue was crushed using petroleum ether (50 mL) and the residue was filtered 
to give 3.12 as an off white solid (6809 mg, 17.44 mmol, 95%). 1H NMR (300 MHz, DMSO-
d6): 2.01 (s, 3H, COCH3), 3.53 (m, 4H, SCH2; Ph-CH2), 4.69 (d, Jgem = 12.7 Hz, 1H, 
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CH2OAc), 5.04 (d, Jgem = 12.7 Hz, 1H, CH2OAc), 5.68 (d, J6,7 = 4.9 Hz, 1H, H6), 5.68 (dd, J6,7 
= 4.9 Hz, J7,NH = 8.2 Hz, 1H, H7), 7.26 (m, 5H, Ar), 9.09 (d, J7,NH = 8.2 Hz, 1H, NH). LRMS: 
(ESI,) m/z (relative intensity): 390 ([M]; 7), 389.08 ([MH]; 37) 
 
 
To a suspension of 3.12 (5270 mg, 13.50 mmol) in EtOAc (50 mL) at 0 C was added a 
solution of diphenyldiazomethane 3.14 (14.85 mL, 14.85 mmol, 1M solution in EtOAc) at 
once and the reaction was allowed to stir for overnight gradually warming up to rt. Then the 
solvent was evaporated under reduced pressure and the residue was dissolved in THF (50 mL) 
and filtered. The filtrate was concentrated under reduced pressure in vacuo, the residue was 
washed with little quantity of EtOAc and filtered to give 3.15 (6150 mg, 11.04 mmol, 82%) as 
a white solid residue. 1H NMR (300 MHz, DMSO-d6): 1.98 (s, 3H, COCH3), 3.58 (m, 4H, 
SCH2; Ph-CH2), 4.65 (d, Jgem = 13.1 Hz, 1H, CH2OAc), 4.88 (d, Jgem = 13.1 Hz, 1H, CH2OAc), 
5.15 (d, J6,7 = 4.9 Hz, 1H, H6), 5.79 (dd, J6,7 = 4.9 Hz, J7,NH = 8.2 Hz, 1H, H7), 6.94 (s, 1H, 
CHPh2), 7.36 (m, 15H, Ar), 9.15 (d, J7,NH = 8.2 Hz, 1H, NH). 13C NMR (75.5 MHz, DMSO-
d6): 20.41, 25.85, 41.60, 57.61, 59.07, 62.48, 78.78, 125.03, 126.15, 126.26, 126.51, 126.84, 
127.87, 128.22, 128.38, 128.50, 129.00, 135.77, 139.68, 139.80, 160.54, 165.24, 170.03, 
170.96. 
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To a solution of 3.15 (2000 mg, 3.59 mmol) in dichloromethane (15 mL) at 0 C was added m-
CPBA (965 mg, 1.20 mmol) at once and was gradually warmed to rt in 3 hours. Upon 
completion the solvent was evaporated in vacuo and the residue was dissolved in EtOAc (30 
mL), washed with water (2  30 mL), sat. NaHCO3 (3  30 mL) and brine (2  30 mL). The 
organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. 
Flash chromatography (EtOAc:hexane; 1:2) to give 3.16 (1880 mg, 3.12 mmol, 87%) as a 
white solid. 1H NMR (300 MHz, DMSO-d6): 1.97 (s, 3H, COCH3), 3.64 (m, 3H, SCH2; Ph-
CH2), 3.96 (d, Jgem = 18.7 Hz, 1H, SCH2), 4.61 (d, Jgem = 13.4 Hz, 1H, CH2OAc), 4.93 (d, J6,7 
= 4.3 Hz, 1H, H6), 5.06 (d, Jgem = 13.4 Hz, 1H, CH2OAc), 5.93 (dd, J6,7 = 4.3 Hz, J7,NH = 8.3 
Hz, 1H, H7), 6.95 (s, 1H, CHPh2), 7.33 (m, 15H, Ar) and 8.44 (d, J7,NH = 8.3 Hz, 1H, NH). 13C 
NMR (75.5 MHz, DMSO-d6):20.48, 41.48, 45.47, 58.09, 62.79, 66.49, 79.08, 121.69, 
124.38, 126.55, 126.81, 127.85, 127.92, 128.30, 128.38, 128.54, 129.11, 135.78, 139.78, 
159.80, 164.58, 170.00, 171.12. 
 
Compound 3.16 (50 mg, 0.09 mmol) was dissolved in a mixture of DMSO-d6 (1000 µL) and 
methanol-d4 (36 µL, 0.88 mmol). The mixture was stirred for 90 minutes at 50 C. The solvent 
was evaporated under high vacuum and small aliquot was used to do NMR and then returned 
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back to the reaction flask. Fresh methanol-d4 (36 µL, 0.88 mmol) was added and the reaction 
was repeated for 90 another minutes at 50 C. Upon completion, methanol was evaporated 
under high vacuum to give 3.17 in DMSO-d6. 1H NMR (300 MHz, DMSO-d6; after 90 
minutes): 1.97 (s, 3H, COCH3), 3.63 (m, 2.81H, SCX2, where X=H/D; Ph-CH2), 3.93 (d, 
0.58H, SCX2, where X=H/D), 4.61 (d, Jgem = 13.2 Hz, 1H, CH2OAc), 4.93 (d, J6,7 = 4.9 Hz, 
1H, H6), 5.06 (d, Jgem = 13.2 Hz, 1H, CH2OAc), 5.93 (m, 1H, H7), 6.95 (s, 1H, CHPh2), 7.32 
(m, 15H, Ar), 8.44 (d, J7,NH = 8.5 Hz, 0.6H, NH). 1H NMR (300 MHz, DMSO-d6; after 180 
minutes): 1.96 (s, 3H, COCH3), 3.63 (m, 2.47H, SCX2, where X=H/D; Ph-CH2), 3.93 (d, 
0.25H, SCX2, where X=H/D), 4.61 (d, Jgem = 13.4 Hz, 1H, CH2OAc), 4.92 (d, J6,7 = 4.8 Hz, 
1H, H6), 5.06 (d, Jgem = 13.4 Hz, 1H, CH2OAc), 5.92 (m, 1H, H7), 6.94 (s, 1H, CHPh2), 7.31 
(m, 15H, Ar) and 8.43 (d, J7,NH = 8.5 Hz, 0.3H, NH). 
 
Compound 3.16 (50 mg, 0.09 mmol) was dissolved in a mixture of DMSO-d6 (1000 µL) and 
methanol-d (36 µL, 0.88 mmol). The mixture was stirred for 90 minutes at 50 C. The solvent 
was evaporated under high vacuum and small aliquot was used to do NMR and then returned 
back to the reaction flask. Fresh methanol-d (36 µL, 0.88 mmol) was added and the reaction 
was repeated for another 90 minutes at 50 C. Upon completion methanol was evaporated 
under high vacuum to give 3.17 in DMSO-d6. 1H NMR (300 MHz, DMSO-d6; after 90 
minutes): 1.97 (s, 3H, COCH3), 3.63 (m, 2.83H, SCX2, where X=H/D; Ph-CH2), 3.95 (d, 
0.46H, SCX2, where X=H/D), 4.61 (d, Jgem = 13.5 Hz, 1H, CH2OAc), 4.93 (d, J6,7 = 4.8 Hz, 
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1H, H6), 5.06 (d, Jgem = 13.5 Hz, 1H, CH2OAc), 5.92 (m, 1H, H7), 6.95 (s, 1H, CHPh2), 7.33 
(m, 15H, Ar), 8.44 (d, J7,NH = 9.3 Hz, 0.45H, NH). 1H NMR (300 MHz, DMSO-d6; after 180 
minutes): 1.96 (s, 3H, COCH3), 3.64 (m, 2.49H, SCX2, where X=H/D; Ph-CH2), 3.95 (d, 
0.25H, SCX2, where X=H/D), 4.61 (d, Jgem = 13.4 Hz, 1H, CH2OAc), 4.93 (d, J6,7 = 4.8 Hz, 
1H, H6), 5.06 (d, Jgem = 13.4 Hz, 1H, CH2OAc), 5.92 (m, 1H, H7), 6.94 (s, 1H, CHPh2), 7.31 
(m, 15H, Ar), 8.43 (d, J7,NH = 8.5 Hz, 0.3H, NH). 
 
Compound 3.16 (50 mg, 0.09 mmol) was dissolved in a mixture of DMSO-d6 (1000 µL) and 
methanol-d1 (360 µL, 8.80 mmol). The mixture was stirred for 24 hours at 50 C. The solvent 
was evaporated under high vacuum and small aliquot was used to do NMR and then returned 
back to the reaction flask. Fresh methanol-d (360 µL, 8.80 mmol) was added. The reaction was 
repeated for another 19 hours at 50 C. After 19 hours, the solvent was evaporated under high 
vacuum and small aliquot was used to do NMR and then returned back to the reaction flask. 
Fresh new methanol-d (360 µL, 8.80 mmol) was added and the reaction was repeated for 23 
hours more at 50 C. After 23 hours, the solvent was evaporated under high vacuum and small 
aliquot was used to do NMR and then returned back to the reaction flask. Upon completion 
methanol was evaporated under high vacuum. The oil was dissolved in EtOAc (20 mL) and 
washed with water (2  20 mL) and brine (2  20 mL), dried over anhydrous Na2SO4 and 
concentrated under reduced pressure to give 3.17 as a yellow solid. 1H NMR (300 MHz, 
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DMSO-d6; after 24 hours): 1.96 (s, 3H, COCH3), 3.60 (m, 2.08H, SCX2, where X=H/D; Ph-
CH2), 3.91 (s, 0.08H, SCX2, where X=H/D), 4.61 (d, Jgem = 13.4 Hz, 1H, CH2OAc), 4.91 (d, 
J6,7 = 4.9 Hz, 1H, H6), 5.06 (d, Jgem = 13.4 Hz, 1H, CH2OAc), 5.93 (d, J6,7 = 4.9 Hz, 1H, H7), 
6.93 (s, 1H, CHPh2), 7.31 (m, 15H, Ar), 8.38 (d, 0.06H, NH). 1H NMR (300 MHz, DMSO-d6; 
after 43 hours): 1.97 (s, 3H, COCH3), 3.62 (m, 2.06H, SCX2, where X=H/D; Ph-CH2), 3.93 
(s, 0.06H, SCX2, where X=H/D), 4.61 (d, Jgem = 13.4 Hz, 1H, CH2OAc), 4.92 (d, J6,7 = 4.8 Hz, 
1H, H6), 5.06 (d, Jgem = 13.4 Hz, 1H, CH2OAc), 5.93 (d, J6,7 = 4.8 Hz, 1H, H7), 6.95 (s, 1H, 
CHPh2), 7.38 (m, 15H, Ar), 8.45 (d, 0.05H, NH). 1H NMR (300 MHz, DMSO-d6; after 66 
hours): 1.97 (s, 3H, COCH3), 3.64 (m, 2.03H, SCX2, where X=H/D; Ph-CH2), 3.94 (d, 0.03H, 
SCX2, where X=H/D), 4.61 5.06 (d, Jgem = 13.4 Hz, 1H, CH2OAc), 4.93 (d, J6,7 = 4.9 Hz, 1H, 
H6), 5.06 (d, Jgem = 13.4 Hz, 1H, CH2OAc), 5.93 (d, J6,7 = 4.9 Hz 1H, H7), 6.95 (s, 1H, 
CHPh2), 7.36 (m, 15H, Ar), 8.47 (d, 0.05H, NH). 1H NMR (300 MHz, CDCl3; after workup): 
2.01 (s, 3H, COCH3), 3.14 (s, 0.06H, SCX2, where X=H/D), 3.63 (m, 2H, Ph-CH2), 3.75 (s, 
0.07H, SCX2, where X=H/D), 4.42 (d, J6,7 = 4.6 Hz, 1H, H6), 4.70 (d, Jgem = 14.1 Hz, 1H, 
CH2OAc), 5.26 (d, Jgem = 14.1 Hz, 1H, CH2OAc), 6.08 (m, 1H, H7), 6.72 (d, J7,NH = 9.8 Hz 
0.29H, NH), 6.94 (s, 1H, CHPh2), 7.35 (m, 15H, Ar). 
 
Compound 3.16 (200 mg, 0.36 mmol) was dissolved in a mixture of DMSO-d6 (4 mL) and 
methanol-d (1.5 mL, 35.93 mmol). The mixture was stirred for 2 hours at 50 C. The solvent 
was evaporated under high vacuum and new methanol-d (1.5 mL, 35.93 mmol) was added. The 
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reaction was continued for a total of 24 hours at 50 C and every 2 hours from t = 0 hours to t= 
8 hours methanol-d was changed. After 24 hours, methanol was evaporated under high vacuum 
and the oil/DMSO was dissolved in EtOAc (20 mL) and washed with water (2  20 mL) and 
brine (2  20 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure to 
give 3.17 (200 mg, 0.35 mmol, 99%) as a yellow solid. 1H NMR (300 MHz, CDCl3): 2.01 (s, 
3H, COCH3), 3.14 (s, 0.03H, SCX2, where X=H/D), 3.63 (m, 2H, Ph-CH2), 3.75 (s, 0.07H, 
SCX2, where X=H/D), 4.43 (d, J6,7 = 4.8 Hz, 1H, H6), 4.70 (d, Jgem = 14.1 Hz, 1H, CH2OAc), 
5.26 (d, Jgem = 14.1 Hz, 1H, CH2OAc), 6.07 (m, 1H, H7), 6.68 (d, J7,NH = 9.9 Hz, 0.28H, NH), 
6.94 (s, 1H, CHPh2), 7.33 (m, 15H, Ar). 13C NMR (75.5 MHz, CDCl3):20.78, 43.50, 59.21, 
63.37, 66.90, 80.49, 121.15, 125.53, 127.22, 127.71, 127.74, 128.33, 128.40, 128.65, 128.75, 
129.18, 129.51, 133.77, 139.00, 139.12, 159.79, 164.23, 170.52, 171.47. 
 
To a solution of 3.1 (260 mg, 0.50 mmol) in 2:1 mixture of dichloromethane:THF (4 ml:2 mL) 
at 0 C was added TEMPO (8 mg, 0.05 mmol) at once and allowed to stir for 5 minutes. BAIB 
(177 mg, 0.55 mmol) was added at once and the reaction was allowed to gradually warm up to 
rt in 3 hours. Upon completion the solvent was evaporated in vacuo and the residue was 
dissolved in dichlormethane (4 mL), crushed out using hexanes (25 mL) and filtered to give 
3.18 as a yellow solid (200 mg, 0.39 mmol, 77%). 1H NMR (300 MHz, CDCl3): 3.23 (d, Jgem 
= 18.5 Hz, 1H, SCH2), 3.83 (s, 2H, thiophene-CH2), 3.95 (d, Jgem = 18.5 Hz, 1H, SCH2), 5.00 
(d, J6,7 = 5.3 Hz, 1H, H6), 5.98 (dd, J6,7 = 5.3 Hz, J7,NH = 8.8 Hz, 1H, H7), 6.60 (d, J7,NH = 8.8 
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Hz, 1H, NH) 6.99 (m, 3H, CHPh2; thiophene), 7.30 (m, 11H, Ar, thiophene), 9.63 (s, 1H, 
CHO). 
 
A solution of 3.18 (222 mg, 0.43 mmol) in methanol (4 mL) was cooled down to 0 C and 
NaBD4 (18 mg, 0.43 mmol) was added to reaction at once. The reaction was stirred for an hour. 
The solvent was evaporated in vacuo and the residue was dissolved in EtOAc (20 mL), washed 
with H2O (3  20 mL) and brine (30 mL). The organic layer was dried over anhydrous Na2SO4 
and concentrated under reduced pressure to give 3.19 (20 mg, 0.04 mmol, 8%). The reaction 
yield was low, due to the formation of lactone and also cleavage of -lactam ring. 
 
Compound 3.20 was obtained from Dr. Ahmad Ghavami. 1H NMR (300 MHz, CDCl3): 3.53 
(s, 2H, SCH2), 3.64 (m, 2H, Ph-CH2), 3.92 (d, Jgem = 12.9 Hz, 1H, CH2OH), 4.38 (d, Jgem = 
12.9 Hz, 1H, CH2OH), 4.92 (d, J6,7 = 4.8 Hz, 1H, H6), 5.88 (dd, J6,7 = 4.8 Hz, J7,NH = 9.1 Hz, 
1H, H7), 6.16 (d, J7,NH = 9.1 Hz, 1H, NH), 6.9 (s, 1H, CHPh2), 7.34 (m, 15H, Ar). 
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To a solution of 3.20 (520 mg, 1.00 mmol) in 2:1 mixture of dichloromethane:THF (6 ml: 
3mL) at 0 C was added TEMPO (16 mg, 0.10 mmol) at once and allowed to stir for 5 minutes. 
BAIB (354 mg, 1.10 mmol) was added at once and the reaction was allowed to gradually warm 
up to rt in 3 hours. Upon completion the solvent was evaporated in vacuo and the residue was 
dissolved in dichloromethane (10 mL), crushed out using hexanes (50 mL) and filtered to give 
3.21 as a yellow solid (440 mg, 0.85 mmol, 85%). 1H NMR (300 MHz, CDCl3): 3.25 (d, Jgem 
= 18.4 Hz, 1H, SCH2), 3.65 (m, 2H, Ph-CH2), 3.96 (d, Jgem = 18.4 Hz, 1H, SCH2), 5.02 (d, J6,7 
= 5.2 Hz, 1H, H6), 5.98 (dd, J6,7 = 5.2 Hz, J7,NH = 9.2 Hz, 1H, H7), 6.09 (d, J7,NH = 9.2 Hz, 1H, 
NH) 7.06 (s, 1H, CHPh2), 7.32 (m, 15H, Ar), 9.62 (s, 1H, CHO). 
 
A solution of 3.21 (50 mg, 0.1 mmol) in ethanol (4 mL) was cooled down to 0 C and NaBH4 
(4 mg, 0.1 mmol) was added to the reaction mixture at once. The reaction was allowed to stir 
for 30 minutes. Upon completion 0.1 N HCl (5 mL) was added to adjust the pH to 4.0 and then 
the solvent was evaporated in vacuo. The residue was extracted with EtOAc (3  10 mL). The 
combined organic phase was washed with brine (20 mL), dried over anhydrous Na2SO4 and 
concentrated under reduced pressure to give 3.20 (30 mg, 0.05 mmol, 50%). 1H NMR (300 
MHz, CDCl3): 3.53 (m, 4H, SCH2; Ph-CH2), 4.81 (m, 2H, CH2OH), 4.98 (d, J6,7 = 5.0 Hz, 
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1H, H6), 5.91 (dd, J6,7 = 5.0 Hz, J7,NH = 8.5 Hz, 1H, H7), 6.16 (d, J7,NH = 8.5 Hz, 1H, NH), 7.28 
(m, 16H, CHPh2; Ar). 
 
To the solution of benzaldehyde 3.22 (250 mg, 2.35 mmol) in ethanol (5 mL) was added 
NaBH4 (89 mg, 2.35 mmol) at once and allowed to react for 15 minutes. Upon completion the 
reaction was acidified to pH of 3.0 using acetic acid (3 mL). The solvent was evaporated in 
vacuo and the residue was extracted with EtOAc (3  10 mL). The combined organic phase 
was washed with brine (20 mL), dried over anhydrous Na2SO4 and concentrated under reduced 
pressure to give 3.23 (236 mg, 2.18 mmol, 92%) as colourless oil. 1H NMR (300 MHz, 
DMSO-d6): 5.1 (s, 2H, CH2OH), 7.79 (m, 5H, Ar). 13C NMR (75.5 MHz, DMSO-d6): 
65.16, 127.05, 127.65, 128.57. 
 
To the solution of benzaldehyde 3.22 (250 mg, 2.35 mmol) in ethanol (5 mL) was added 
NaBD4 (99 mg, 2.35 mmol) at once and allowed to react for 15 minutes. Upon completion the 
reaction was acidified to pH of 3.0 using acetic acid (3 mL). The solvent was evaporated in 
vacuo and the residue was extracted with EtOAc (3  10 mL). The combined organic phase 
was washed with brine (20 mL), dried over anhydrous Na2SO4 and concentrated under reduced 
pressure to give 3.24 (218 mg, 2.0 mmol, 85%) as colourless oil. 1H NMR (300 MHz, DMSO-
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d6):  4.15 (s, 1H, CDHOH), (s, 1H, CDHOH), 7.83 (m, 5H, Ar). 13C NMR (75.5 MHz, 
DMSO-d6): 64.30, 64.60, 64.88 (t, 1C, CDHOH), 127.00, 127.50, 128.45. 
. 
To a suspension of 3.11 (12000 mg, 44.06 mmol) in methanol (120 mL) and water (120 mL) at 
30 C was added, aqueous NaOH (2650 mg, 66.09 mmol) in water (10 mL) dropwise over a 
period of 30 minutes. The reaction was allowed to stir at same temperature of extra 30 minutes. 
The pH was adjusted to 3.0 by adding conc. HCl (10 mL). Upon acidification the solution was 
filtered and washed with methanol and acetone several times to give 3.25 (8000 mg, 34.74 
mmol, 80%) as a yellow solid. 1H NMR (300 MHz, D2O): 3.53 (d, Jgem = 18.6 Hz, 1H, 
SCH2), 3.67 (d, Jgem = 18.6 Hz, 1H, SCH2), 4.98 (d, J6,7 = 5.1 Hz, 1H, H6), 5.04 (d, J6,7 = 5.1 
Hz, 1H, H7), Peak for CH2OH under solvent peak.  
 
To a solution of 3.25 (7000 mg, 34.74 mmol) in DMF (80 mL) at rt was added, BSA (18.78 
mL, 76 mmol) at once and was allowed to stir for 30 minutes, this was then cooled down to 
40 C. Phenylacetyl chloride (6.04 mL, 52.11 mmol) was added drop wise to above reaction 
mixture and it was stirred for 3 hours at 40 C. Upon completion the reaction was poured into 
ice cold H2O (50 mL) and extracted with EtOAc (4  80 mL). The combined organic phase 
was washed with brine (5  50 mL), dried over anhydrous Na2SO4 and concentrated under 
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reduced pressure to give 3.26 (6376 mg, 18.30 mmol, 60%) as a yellow oil. Crushed out using 
diethyl ether (50 mL) and filtered to get solid residue. 1H NMR (300 MHz, DMSO-d6):  3.55 
(m, 4H, SCH2; Ph-CH2), 4.25 (m, 2H, CH2OH), 5.04 (d, J6,7 = 4.7 Hz, 1H, H6), 5.62 (dd, J6,7 = 
4.7 Hz, J7,NH = 8.3 Hz, 1H, H7), 7.26 (m, 5H, Ar), 9.06 (d, J7,NH =8.3 Hz, 1H, NH). 
 
To a suspension of 3.26 (2700 mg, 7.75 mmol) in EtOAc (30 mL) at 0 C was added a solution 
of diphenyldiazomethane 3.14 (9.4 mL, 9.4 mmol, 1 M solution in EtOAc) at once and it was 
allowed to stir overnight and gradually warmed up to rt. Upon completion the solvent was 
evaporated under reduced pressure, the residue was dissolved in THF (30 mL) and filtered. The 
filtrate was concentrated under reduced pressure in vacuo. The residue was washed with little 
quantity of EtOAc and filtered to give 3.20 (3000 mg, 5.82 mmol, 75%) as a white solid. 1H 
NMR (300 MHz, DMSO-d6): 3.56 (m, 4H, SCH2; Ph-CH2), 4.21 (m, 2H, CH2OH), 5.13 (m, 
2H, H6; CH2OH), 5.71 (dd, J6,7 = 4.8 Hz, J7,NH = 8.3 Hz, 1H, H7), 6.90 (s, 1H, CHPh2), 7.32 
(m, 15H, Ar), 9.11 (d, J7,NH = 8.3Hz, 1H, NH). 1H NMR (300 MHz, benzene-d6): 3.39 (d, 
Jgem = 18.1 Hz, 1H, SCH2), 3.58 (d, Jgem = 18.1 Hz, 1H, SCH2), 3.69 (m, 2H, Ph-CH2), 4.43 
(dd, Jgem = 14.4 Hz, J3,OH = 6.2 Hz, 1H, CH2OH), 4.55 (m, 2H, H6; CH2OH), 4.88 (t, J = 6.0, 
1H, CH2OH), 5.80 (dd, J6,7 = 4.8 Hz, J7,NH = 8.2 Hz, 1H, H7), 7.08 (m, 10H, CHPh2; Ar), 7.44 
(t, J = 7.6 Hz, 4H, Ar), 7.61 (d, J = 7.6, 2H, Ar), 9.08 (d, J7,NH = 8.2 Hz, 1H, NH). 1H NMR 
(500 MHz, acetone-d6): 3.68 (m, 4H, SCH2; Ph-CH2), 4.09 (t, J = 6.0, 1H, CH2OH), 4.31 (dd, 
Jgem = 13.7 Hz, J3,OH = 6.2 Hz, 1H, CH2OH), 4.42 (dd, Jgem = 13.7 Hz, J3,OH = 6.2 Hz, 1H, 
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CH2OH), 5.12 (d, J6,7 = 4.8 Hz, 1H, H6), 5.85 (dd, J6,7 = 4.8 Hz, J7,NH = 8.7 Hz, 1H, H7), 6.91 
(s, 1H, CHPh2), 7.35 (m, 15H, Ar), 7.99 (d, J7,NH = 8.7 Hz, 1H, NH). 
2 2 2 2  
To a solution of 3.20 (1029 mg, 2.00 mmol) in 2:1 mixture of dichloromethane:THF (14 ml:7 
mL) at 0 C was added TEMPO (63 mg, 0.40 mmol) at once and allowed to stir for 5 minutes. 
BAIB (709 mg, 2.20 mmol) was added at once and the reaction was allowed to gradually warm 
to rt in 4 hours. Upon completion the solvent was evaporated in vacuo, the residue was 
dissolved in dichloromethane (10 mL), crushed out using hexanes (50 mL) and filtered to give 
3.21 as a yellow solid (923 mg, 1.80 mmol, 90%). 1H NMR (300 MHz, CDCl3): 3.26 (d, Jgem 
= 18.4 Hz, 1H, SCH2), 3.96 (d, Jgem = 18.4 Hz, 1H, SCH2), 3.67 (qAB, J = 16.3 Hz, 2H, Ph-
CH2), 5.03 (d, J6,7 = 4.8 Hz, 1H, H6), 6.0 (m, 2H, H7; NH), 7.06 (s, 1H, CHPh2), 7.32 (m, 15H, 
Ar), 9.62 (s, 1H, CHO). 
 
To a solution of 3.21 (500 mg, 1.08 mmol) in methanol (15 mL) at 30 C was added NaBD4 
(45 mg, 1.08 mmol) at once and it was allowed to stir at the same temperature for 30 minutes. 
Upon completion sat. NH4Cl solution (5 mL) was added to make it acidic and then the solvent 
was evaporated under high vacuum very carefully. The suspension was extracted with ethyl 
acetate (3  10 mL). The combined organic phase was washed with brine (20 mL), dried over 
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anhydrous Na2SO4 and concentrated under reduced pressure. The residue was washed with 
little quantity of EtOAc and filtered to give 3.27 (300 mg, 0.58 mmol, 60%) as a white solid. 
1H NMR (300 MHz, DMSO-d6): 3.55 (m, 4H, SCH2; Ph-CH2), 4.18 (m, 1H, CHDOH), 5.13 
(m, 2H, H6; CDHOH), 5.91 (dd, J6,7 = 4.7 Hz, J7,NH = 8.3 Hz, 1H, H7), 6.9 (s, 1H, CHPh2), 
7.32 (m, 15H, Ar), 9.12 (d, J7,NH = 8.3 Hz, 1H, NH). 13C NMR (75.5 MHz, DMSO-d6): 
25.55, 41.57, 57.70, 58.90, 78.32, 122.00, 126.47, 126.55, 126.59, 126.76, 127.76, 127.82, 
128.21, 128.37, 128.50, 129.00, 134.36, 135.81, 139.96, 140.03, 160.86, 165.21, 170.95.    
 
To a solution of 3.27 (50 mg, 0.10 mmol) in 2:1 mixture of dichloromethane:THF (4 ml:2 mL) 
at 0 C was added TEMPO (3 mg, 0.01 mmol) at once and allowed to stir for 5 minutes. BAIB 
(34 mg, 0.10 mmol) was added at once and the reaction was allowed to gradually warm to rt in 
24 hours. Upon completion the solvent was evaporated in vacuo, the residue was dissolved in 
dichloromethane (10 mL), crushed out using hexanes (50 mL) and filtered to give 3.28 (45 mg, 
0.09 mmol, 90%) as a yellow solid. 1H NMR (300 MHz, CDCl3): 3.22 (d, Jgem = 18.6 Hz, 1H, 
SCH2), 3.64 (m, 2H, Ph-CH2), 3.94 (d, Jgem = 18.6 Hz, 1H, SCH2), 4.99 (d, J6,7 = 5.3 Hz, 1H, 
H6), 5.97 (dd, J6,7 = 5.3 Hz, J7,NH = 9.1 Hz, 1H, H7), 6.38 (d, J7,NH = 9.1 Hz, 1H, NH), 7.07 (s, 
1H, CHPh2), 7.32 (m, 15H, Ar), 9.62 (s, 0.5H and 0.5D, CXO, where X = H/D). 13C NMR 
(75.5 MHz, CDCl3): 22.32, 43.28, 59.09, 59.97, 80.92, 124.04, 127.16, 127.92, 127.97, 
128.58, 128.69, 128.74, 128.81, 129.32, 129.52, 133.58, 138.21, 138.48, 138.53, 159.75, 
165.34, 171.33, 187.84. 
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3.16 (1145.2 mg, 2.00 mmol) was dissolved in a mixture of DMSO (20 mL) and methanol-d (4 
mL, 100.00 mmol). The mixture was stirred for 16 hours at 50 C. The solvent was evaporated 
under high vacuum and new methanol-d (4 mL, 100.00 mmol) was added. The reaction was 
repeated for 8 hours at 50 C. After 24 hours, methanol was evaporated under high vacuum. 
The oil was dissolved in EtOAc (20 mL) and washed with water (2  20 mL) and brine (2  20 
mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure to give 3.17 (1137 
mg, 1.97 mmol, 99%) as a yellow solid. 1H NMR (300 MHz, CDCl3): 2.01 (s, 3H, COCH3), 
3.15 (s, 0.04H, SCX2, where X=H/D), 3.64 (m, 2H, Ph-CH2), 3.76 (s, 0.07H, SCX2, where 
X=H/D), 4.43 (d, J6,7 = 4.6 Hz, 1H, H6), 4.70 (d, Jgem = 14.3 Hz, 1H, CH2OAc), 5.27 (d, Jgem = 
14.3 Hz, 1H, CH2OAc), 6.10 (m, 1H, H7), 6.72 (d, J7,NH = 9.9 Hz, 0.49H, NH), 6.93 (s, 1H, 
CHPh2), 7.36 (m, 15H, Ar).  
 
To a solution of 3.17 (970 mg, 1.69 mmol) in DMF (40 mL) at 30 C was added PCl3 (310 
µL, 3.55 mmol) drop wise and allowed to react for 30 minutes. The reaction mixture was 
poured into ice cold H2O (30 mL) and the compound was extracted with EtOAc (3  40 mL). 
The combined organic phase was washed with brine (4  30 mL), dried over anhydrous 
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Na2SO4 and concentrated under reduced pressure. The residue was crushed using diethyl ether 
(40 mL) and filtered to give 3.39 (890 mg, 1.59 mmol, 95%) as a white solid. 1H NMR (300 
MHz, CDCl3): 2.01 (s, 3H, COCH3), 3.30 (s, 0.04H, SCX2, where X=H/D), 3.49 (s, 0.04H, 
SCX2, where X=H/D), 3.64 (m, 2H, Ph-CH2), 4.94 (d, J6,7 = 4.9 Hz, 1H, H6), 4.76 (d, Jgem = 
13.6 Hz, 1H, CH2OAc), 5.00 (d, Jgem = 13.6 Hz, 1H, CH2OAc), 5.86 (dd, J6,7 = 4.9 Hz, J7,NH = 
9.1 Hz, 1H, H7), 6.12 (d, J7,NH = 9.1 Hz, 1H, NH), 6.92 (s, 1H, CHPh2), 7.32 (m, 15H, Ar).  
 
To a solution of 3.39 (890 mg, 1.59 mmol) in dichloromethane (20 mL) at 0 C, trifluoroacetic 
acid (2.40 mL, 31.86 mmol) and anisole (0.70 mL, 6.37 mmol) was added to the reaction at 
once and it was stirred for 30 minutes at same temperature. Upon completion all the solvent 
was concentrated under reduced pressure and the residue was triturated with diethyl ether 5-6 
times to give 3.40 (469 mg, 1.19 mmol, 75%) as a yellow solid. 1H NMR (300 MHz, Acetone-
d6): 2.03 (s, 3H, COCH3), 3.67 (m, 2H, Ph-CH2), 5.12 (d, J6-7 = 4.9 Hz, 1H, H6), 4.81 (d, J = 
13.1 Hz, 1H, CH2OAc), 5.1 (d, J = 13.1 Hz, 1H, CH2OAc), 5.84 (dd, J6,7 = 4.9 Hz, J7,NH = 8.4 
Hz, 1H, H7), 7.28 (m, 5H, Ar), 8.04 (d, J7,NH = 8.4 Hz, 1H, NH). 
 
To a mixture of water (2.5 mL) and methanol (1.8 mL) cooled to 20 C was added 3.40 (460 
mg, 1.17 mmol). Cooled solution of sodium hydroxide (70 mg, 1.76 mmol) in water (0.5 mL) 
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was added to above reaction drop wise using syringe pump in 40 minutes at 20 C. After 
addition the reaction was stirred for another 40 minutes and then it was diluted with EtOAc (10 
mL) and then acidified to pH of 2.0 using 10% HCl (2 mL). The organic layer was separated 
and aqueous layer was extracted with EtOAc (2  20 mL). The combined organic phase was 
washed with brine (2  30 mL), dried over anhydrous Na2SO4 and concentrated under reduced 
pressure. EtOAc was added to the residue and it was filtered to give 3.41 (124 mg, 0.35 mmol, 
35%) as a white solid. 1H NMR (300 MHz, DMSO-d6): 3.54 (m, 2H, Ph-CH2), 4.25 (m, 2H, 
CH2OH), 5.04 (d, J6,7 = 4.8 Hz, 1H, H6), 5.62 (dd, J6,7 = 4.8 Hz, J7,NH = 8.3 Hz, 1H, H7), 7.25 
(m, 5H, Ar), 9.09 (d, J7,NH = 8.3 Hz, 1H, NH). 
 
To a suspension of 3.41 (119 mg, 0.34 mmol) in EtOAc (10 mL) at 0 C. was added solution of 
diphenyldiazomethane (0.40 mL, 0.40 mmol, 1M solution in EtOAc) at once and the reaction 
was allowed to stir for overnight gradually warming up to rt. Upon completion the solvent was 
evaporated under reduced pressure and the residue was dissolved in THF (20 mL) and filtered. 
The filtrate was concentrated under reduced pressure, the residue was washed with little 
quantity of EtOAc and filtered to give 3.42 (125 mg, 0.24 mmol, 72%) as a white solid. 1H 
NMR (300 MHz, Acetone-d6): 3.65 (m, 2H, Ph-CH2), 4.11 (t, J = 6.2 Hz, 1H, CH2OH), 4.37 
(m, 2H, CH2OH), 5.12 (d, J6,7 = 4.8 Hz, 1H, H6), 5.85 (dd, J6,7 = 4.8 Hz, J7,NH = 8.8 Hz, 1H, 
H7), 6.91 (s, 1H, CHPh2), 7.32 (m, 15H, Ar), 8.02 (d, J7,NH = 8.8 Hz, 1H, NH). 
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To a solution of 3.42 (119 mg, 0.23 mmol) in 2:1 mixture of dichloromethane:THF (4 ml:2 
mL) at 0 C was added TEMPO (8 mg, 0.05 mmol) at once and allowed to stir for 5 minutes. 
BAIB (82 mg, 0.25 mmol) was added at once and the reaction was allowed to gradually warm 
to rt in 4 hours. Upon completion the solvent was evaporated in vacuo, the residue was 
dissolved in dichloromethane (5 mL), crushed out using hexanes (20 mL) and filtered to give 
3.43 as a yellow solid (115 mg, 0.22 mmol, 97%). 1H NMR (300 MHz, CDCl3): 3.24 (s, 
0.05H, SCX2, where X=H/D), 3.66 (m, 2H, Ph-CH2), 3.94 (s, 0.05H, SCX2, where X=H/D), 
5.03 (d, J6,7 = 4.5 Hz, 1H, H6), 6.1 (m, 2H, H6; NH), 7.06 (s, 1H, CHPh2), 7.30 (m, 15H, Ar), 
9.62 (s, 1H, CHO). 
 
To a solution of 3.43 (110 mg, 0.21 mmol) in methanol (5 mL) at 30 C was added NaBD4 (9 
mg, 0.21 mmol) to the reaction at once and it was allowed to react at same temperature for 30 
minutes. Upon completion sat. NH4Cl solution (5 mL) was added to make it acidic and then the 
solvent was evaporated under vacuum pump very carefully. The suspension was extracted with 
EtOAc (3  10 mL). The combined organic phase was washed with brine (2  10 mL), dried 
over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was suspended 
in EtOAc and filtered to give 3.44 (60 mg, 0.12 mmol, 50%) as a white solid residue. 1H NMR 
(300 MHz, Acetone-d6): 3.67 (m, 2H, Ph-CH2), 4.09 (d, J = 6.1 Hz, 1H, CH2OH), 4.37 (m, 
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1H, CDHOH), 5.12 (d, J6,7 = 4.9 Hz, 1H, H6), 5.86 (dd, J6,7 = 4.9 Hz, J7,NH = 8.7 Hz, 1H, H7), 
6.91 (s, 1H, CHPh2), 7.37 (m, 15H, Ar), 8.02 (d, J7,NH = 8.7 Hz, 1H, NH). 
 
To a suspension of 3.12 (7800 mg, 20 mmol) in dichloromethane (400 mL) at 0 C, m-CPBA 
(4500 mg, 26 mmol) was added to the reaction at once and was gradually warmed to rt in 3 
hours. Upon completion the reaction was filtered and residue was washed with 
dichloromethane (2  100 mL), dried under vacuum pump to give 3.45 (7910 mg, 19.46 mmol, 
97%) as a white solid. 1H NMR (300 MHz, DMSO-d6): 2.02 (s, 3H, COCH3), 3.54 (m, 3H, 
SCH2; Ph-CH2), 3.89 (d, Jgem = 18.2 Hz, 1H, SCH2), 4.59 (d, Jgem = 13.3 Hz, 1H, CH2OAc), 
5.2 (d, Jgem = 13.3 Hz, 1H, CH2OAc), 4.85 (d, J6,7 = 4.4 Hz, 1H, H6), 5.8 (dd, J6,7 = 4.4 Hz, 
J7,NH = 8.2 Hz, 1H, H7), 7.27 (m, 5H, Ar), 8.43 (d, J7,NH = 8.2 Hz, 1H, NH). LRMS: (ESI) m/z 
(relative intensity): 406.08 ([M], 20), 405.07 ([MH], 100). 
 
3.45 (5000 mg, 12.30 mmol) was dissolved in a mixture of DMSO (60 mL) and methanol-d 
(10.0 mL, 246.00 mmol). The mixture was stirred for 2 hours at 50 C. The solvent was 
evaporated under high vacuum and new methanol-d (10.0 mL, 246.00 mmol) was added. The 
reaction was repeated for 2 hours at 50 C and the same procedure was repeated for the third 
set of 2 hours. After 6 hours, methanol was evaporated under high vacuum. EtOAc was added 
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to this solution and acidified to pH of 2.0 with 10% HCl (20 mL). The organic layer was 
separated and the aqueous layer was extracted with EtOAc (3  50 mL). The combined organic 
phase was washed with brine (2  20 mL), dried over anhydrous Na2SO4 and concentrated 
under reduced pressure to give 3.46 (4974 mg, 12.17 mmol, 99%) as a yellow solid. 1H NMR 
(300 MHz, DMSO-d6): 2.02 (s, 3H, COCH3), 3.17 (s, 0.03H, SCX2, where X=H/D), 3.62 
(qAB, J = 14.1 Hz, 2H, Ph-CH2), 3.86 (s, 0.03H, SCX2, where X=H/D), 4.59 (d, Jgem = 13.3 
Hz, 1H, CH2OAc), 5.2 (d, Jgem = 13.3 Hz, 1H, CH2OAc), 4.86 (d, J6,7 = 4.8 Hz, 1H, H6), 5.8 
(dd, J6,7 = 4.8 Hz, J7,NH = 8.2 Hz, 1H, H7), 7.26 (m, 5H, Ar), 8.43 (d, J7,NH = 8.2 Hz, 0.49H, 
NH). 13C NMR (75.5 MHz, DMSO-d6):20.66, 41.47, 58.19, 63.08, 66.27, 118.55, 125.99, 
126.58, 128.32, 129.14, 135.86, 162.13, 164.23, 170.18, 171.10. HRMS: (ESI) m/z: 406.0799 
obsd; 406.0835 calcd for C18H16N2O7S;. (Back exchange during ionization). 
 
To a solution of 3.46 (3400 mg, 8.32 mmol) in DMF (50 mL) at 30 C, phosphorus 
trichloride (1.5 mL, 17.48 mmol) was added dropwise to the above reaction and it was allowed 
to react for 30 minutes. The reaction mixture was poured into ice cold H2O (40 mL) and the 
compound was extracted with EtOAc (3  50 mL). The combined organic phase was washed 
with brine (4  30 mL) to remove all left over DMF, dried over anhydrous Na2SO4 and 
concentrated under reduced pressure. The residue was crushed using diethyl ether (50 mL) and 
filtered to give 3.40 (2600 mg, 6.62 mmol, 80%) as a white solid. 1H NMR (300 MHz, DMSO-
d6): 2.03 (s, 3H, COCH3), 3.52 (d, J = 13.7 Hz, 2H, Ph-CH2), 4.68 (d, Jgem = 12.7 Hz, 1H, 
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CH2OAc), 5.01 (d, Jgem = 12.7 Hz, 1H, CH2OAc), 5.09 (d, J6,7 = 4.9 Hz, 1H, H6), 5.69 (dd, J6,7 
= 4.9 Hz, J7,NH = 8.3 Hz, 1H, H7), 7.26 (m, 5H, Ar), 9.11 (d, J7,NH = 8.3 Hz, 1H, NH). 13C 
NMR (75.5 MHz, DMSO-d6):20.60, 41.60, 57.43, 59.09, 62.70, 123.32, 126.40, 126.52, 
128.26, 129.04, 135.83, 162.87, 164.83, 170.24, 170.98. HRMS: (ESI) m/z: 391.0916 obsd; 
391.0938 calcd for C18H15D2N2O6S 
  
To a mixture of water (11.7 mL) and methanol (8.8 mL) cooled to 20 C was added 3.40 
(2300 mg, 5.86 mmol). Cooled solution of NaOH (500 mg, 12.30 mmol) in water (2.4 mL) was 
added to above reaction using syringe pump in 40 minutes at 20 C. After addition the 
reaction was stirred for another 40 minutes, diluted with EtOAc (30 mL) and then acidified to 
pH of 2.0 using 10% HCl (10 mL). The organic layer was separated and aqueous layer was 
extracted with EtOAc (2  30 mL). The combined organic phase was washed with brine (2  
20 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. EtOAc was 
added to the residue and it was filtered to give 3.41 (1000 mg,  2.85 mmol, 50%) as white 
solid. 1H NMR (300 MHz, DMSO-d6): 3.54 (m, 2H, Ph-CH2), 4.25 (m, 2H, CH2OH), 5.04 (d, 
J6,7 = 4.5 Hz, 1H, H6), 5.62 (dd, J6,7 = 4.5 Hz, J7,NH = 8.3 Hz, 1H, H7), 7.25 (m, 5H, Ar), 9.09 
(d, J7,NH = 8.25 Hz, 1H, NH). 13C NMR (75.5 MHz, DMSO-d6):41.58, 57.47, 58.93, 59.85, 
123.40, 126.51, 128.25, 129.04, 131.10, 135.87, 163.28, 164.80, 170.99. HRMS: (ESI) m/z: 
349.0810 obsd; 349.0833 calcd for C16H13D2N2O5S. 
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To a suspension of 3.41 (980 mg, 2.79 mmol) in EtOAc (30 mL) at 0 C was added a solution 
of diphenyldiazomethane (3.4 mL, 3.40 mmol, 1M solution in EtOAc) at once and the reaction 
was allowed to stir overnight, gradually warming up to rt. Upon completion the solvent was 
evaporated under reduced pressure and the residue was dissolved in THF (30 mL) and filtered. 
The filtrate was concentrated under reduced pressure in vacuo. The residue was washed with 
little quantity of EtOAc and filtered to give 3.42 (1300 mg,  2.51 mmol, 90%) as a white solid. 
1H NMR (300 MHz, DMSO-d6): 3.53 (m, 2H, Ph-CH2), 4.21 (d, Jgem = 4.5 Hz, 2H, CH2OH), 
5.14 (m, 2H, H6; CH2OH)), 5.71 (dd, J6,7 = 5.1 Hz, J7,NH = 7.9 Hz, 1H, H7), 6.91 (s, 1H, 
CHPh2), 7.38 (m, 15H, Ar), 9.12 (d, J7,NH = 7.9 Hz, 1H, NH).  
 
To a solution of 3.42 (1290 mg, 2.50 mmol) in 2:1 mixture of dichloromethane:THF (20 ml:10 
mL) at 0 C was added TEMPO (78 mg, 0.50 mmol) at once and allowed to stir for 5 minutes. 
BAIB (965 mg, 2.99 mmol) was added at once and the reaction was allowed to gradually warm 
to rt in 4 hours. Upon completion the solvent was evaporated in vacuo, the residue was 
dissolved in dichloromethane (10 mL), crushed out using hexanes (50 mL) and filtered to give 
3.43 as a yellow solid (1258 mg, 2.44 mmol, 98%). 1H NMR (300 MHz, CDCl3): 3.22 (s, 
0.05H, SCX2, where X=H/D), 3.64 (m, 2H, Ph-CH2), 3.93 (s, 0.05H, SCX2, where X=H/D), 
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5.01 (d, J6,7 = 5.0 Hz, 1H, H6), 5.98 (m, 1H, H7), 6.21 (d, J7,NH = 8.5 Hz, 1H, NH), 7.05 (s, 1H, 
CHPh2), 7.30 (m, 15H, Ar), 9.62 (s, 1H, CHO).  
 
To a solution of 3.43 (1100 mg, 2.45 mmol) in methanol (30 mL) at 30 C was added NaBD4 
(103 mg, 2.45 mmol) at once and it was allowed to react at same temperature for 30 minutes. 
Upon completion sat. NH4Cl solution (20 mL) was added to make it acidic and then the solvent 
was evaporated under high vacuum very carefully. The suspension was extracted with EtOAc 
(3  10 mL) and the combined organic phase was washed with brine (30 mL). The organic 
layer was dried over anhydrous Na2SO4, concentrated under reduced pressure. The residue was 
suspended in EtOAc and filtered to give 3.44 (680 mg, 2.12 mmol, 62%) as a white solid 
residue. 1H NMR (500 MHz, DMSO-d6): 3.55 (m, 2H, Ph-CH2), 4.22 (m, 1H, CDHOH), 5.11 
(d, J = 4.7 Hz, 1H, CH2OH), 5.2 (d, J6,7 = 5.2 Hz, 1H, H6), 5.71 (dd, J6,7 = 5.2 Hz, J7,NH = 8.3 
Hz, 1H, H7), 6.90 (s, 1H, CHPh2), 7.34 (m, 15H, Ar), 9.14 (d, J7,NH = 8.3 Hz, 1H, NH). 1H 
NMR (300 MHz, benzene-d6): 3.39 (s, 0.05H, SCH2), 3.55 (d, 0.06H, SCH2), 3.69 (m, 2H, 
Ph-CH2), 4.44 (m, 0.31H, CHDOH), 4.56 (m, 1.80H, H6; CDHOH), 4.88 (d, J = 5.8, 1H, 
CHDOH), 5.80 (dd, J6,7 = 4.7 Hz, J7,NH = 8.2 Hz, 1H, H7), 7.09 (m, 10H, CHPh2; Ar), 7.44 (t, J 
= 7.9 Hz, 4H, Ar), 7.61 (d, J = 7.5, 2H, Ar), 9.10(d, J7,NH = 8.2 Hz, 1H, NH). 1H NMR (500 
MHz, acetone-d6): 3.67 (m, 2H, Ph-CH2), 4.07 (d, J = 6.0, 1H, CDHOH), 4.28 (m, 0.31H, 
CDHOH), 4.39 (m, 0.8H, CDHOH), 5.12 (d, J6,7 = 4.9 Hz, 1H, H6), 5.85 (dd, J6,7 = 4.9 Hz, 
J7,NH = 8.7 Hz, 1H, H7), 6.91 (s, 1H, CHPh2), 7.35 (m, 15H, Ar), 7.99 (d, J7,NH = 8.7 Hz, 1H, 
NH). 13C NMR (125 MHz, DMSO-d6):25.11, 41.59, 57.69, 58.90, CDHOH (m, 59.1-59.60), 
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78.33, 122.02, 126.47, 128.57, 126.76, 127.77, 127.84, 128.21, 128.38, 128.51, 129.02, 134.61, 
135.83, 139.98, 140.05, 160.87, 165.22, 170.98. HRMS: (+ESI) m/z: 535.2087 obsd; 535.2094 
calcd for C29H27D3N3O5S [M + NH4]+ 
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Appendix B 
NMR Spectrum and Mass Spectrum Images for Certain Compounds 
Figure 3.1: 1H NMR spectrum of 3.4 
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Figure 3.2: 1H NMR spectrum of 3.8 
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Figure 3.3: 1H NMR spectrum of 3.10 (entry 1) 
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Figure 3.4: 1H NMR spectrum of 3.10 (entry 2) 
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Figure 3.5: 1H NMR spectrum of 3.10 (entry 3) 
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Figure 3.6: 1H NMR spectrum of 3.17 (entry 1) 
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Figure 3.7: 1H NMR spectrum of 3.17 (entry 2) 
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Figure 3.8: 1H NMR spectrum of 3.17 (entry 3) 
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Figure 3.9: 1H NMR spectrum of 3.17 (entry 4) 
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Figure 3.10 [A]: 1H NMR spectrum of 3.15  
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Figure 3.10 [B]: 13C NMR spectrum of 3.15  
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Figure 3.10 [C]:  COSY spectrum of 3.15  
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Figure 3.10 [D]:  HMBC spectrum of 3.15  
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Figure 3.11 [A]:  1H NMR spectrum of 3.16  
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Figure 3.11 [B]:  13C NMR spectrum of 3.16  
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Figure 3.11 [C]:  COSY spectrum of 3.16  
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Figure 3.11 [D]:  HMBC spectrum of 3.16  
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Figure 3.12: 1H NMR spectrum of 3.23 
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Figure 3.13 [A]: 1H NMR spectrum of 3.24 
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Figure 3.13 [B]: 13C NMR spectrum of 3.24 
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Figure 3.14: 1H NMR spectrum of 3.27 
 
118 
 
 
Figure 3.15 [A]: 1H NMR spectrum of 3.28 
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Figure 3.15 [B]: 13C NMR spectrum of 3.28 
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Figure 3.16: 1H NMR spectrum of 3.17 (Scheme 3.17) 
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Figure 3.17 [A]: 1H NMR spectrum of 3.44 in DMSO - d6 (Scheme 3.17) 
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Figure 3.17 [B]: 1H NMR spectrum of 3.44 in Acetone - d6 (Scheme 3.17) 
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Figure 3.18 [A]: 1H NMR spectrum of 3.46 
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Figure 3.18 [B]: 13C NMR spectrum of 3.46 
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Figure 3.19 [A]: 1H NMR spectrum of 3.40 (Scheme 3.18) 
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Figure 3.19 [B]: Mass spectrum of 3.40 
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Figure 3.20 [A]: 1H NMR spectrum of 3.44 in Benzene-d6 and drop of DMSO - d6 
(Scheme 3.18) 
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Figure 3.20 [B]: 1H NMR spectrum of 3.44 in Acetone - d6 (Scheme 3.18) 
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Figure 3.20 [C]: 13C NMR spectrum of 3.44 (Scheme 3.18) 
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Figure 3.20 [D]: Mass spectrum of 3.44 (Scheme 3.18) 
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